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7 | SUMMARY OF THE TB BURDEN AND EPIDEMIOLOGIC INDICATORS 
 Tuberculosis Control in the Western Pacific : 2008 Report xi
Executive summary
The status of the tuberculosis (TB) epidemic and progress in control of the disease has been assessed 
annually by the Regional Office for the Western Pacific of the World Health Organization (WHO) since 1997. 
This report presents an overview of progress in reducing the burden of TB in the Western Pacific Region 
(the Region) using data on disease burden and case notifications in 2006 and treatment outcomes for 
patients registered in 2005. 1 Financial data cover the period from 2002 to 2008. The data were collected 
from 35 countries and areas in the Region using the WHO standard form for reporting surveillance data. 
This report highlights the following: 
TB burden: There were an estimated 1.9 million incident cases of TB in 2006 (109 per 100 000 population), 
including 0.9 million new smear-positive cases (45% of the total) and approximately 23 000 TB and human 
immunodeficiency virus (HIV) co-infected cases (1.0% of the total). In absolute terms, China, the Philippines, 
Viet Nam, and Cambodia ranked the first to fourth, respectively. These four countries accounted for 93% of 
the total estimated incident cases in the Region. Cambodia had the highest incidence rate (500 per 100 000 
population). The summary of the data is shown in Table 1.
Trend of prevalence and TB mortality rates towards goal in 2010: Accelerated efforts are needed to 
achieve the goals to halve the prevalence and mortality rates of 2000 by 2010. With the current estimation, 
the prevalence would be 163 [95% confidence interval (CI), 152 to 176] and 14 TB deaths (95% CI, 13 to 15) 
per 100 000 population in 2010, while the prevalence and the mortality rates in 2000 were estimated to be 
261 and 21 per 100 000 population, respectively. 
Case finding: The regional case detection rate for new smear-positive cases in 2006 was sustained high 
at 78% (671 254 new smear-positive cases notified out of the estimated 0.9 million new smear-positive 
cases). Cases from China accounted for 70% of the total notified smear-positive cases. Case detection rates 
in China, the Lao People’s Democratic Republic, Mongolia, the Philippines, and Viet Nam were above the 
70% target. 
Treatment outcomes: Of the 0.7 million new pulmonary smear-positive cases registered for treatment in 
directly observed treatment, short-course (DOTS) areas in 2005, treatment success rate was 92%. Treatment 
success rates were above the 85% target in all countries with a high burden of TB, except Papua New Guinea 
where it was reported at 71%.  
Multidrug-resistant TB 2: Eighteen countries and areas in the Region have conducted drug resistance 
surveillance (DRS) since 2000, and reported the results to the Global Project on Anti-tuberculosis Drug 
Resistance Surveillance. Among new TB cases, the prevalence of multidrug-resistant TB (MDR-TB) ranged 
from 0% in Cambodia to 11.1% in Northern Mariana Islands. MDR-TB prevalence among re-treatment 
cases ranged from 3.1% in Cambodia to 27.5% in Mongolia. In the five countries with a high burden of 
TB with available data from surveys (Cambodia, China, Mongolia, the Philippines, and Viet Nam), MDR-TB 
prevalence in new cases and re-treatment cases ranged from 0% in Cambodia to 4.9% in China 3 and from 
3.1% in Cambodia to 27.5% in Mongolia, respectively. Notably, there were alarming rates of MDR-TB in 
several provinces in China among both new and re-treatment cases. The prevalence of MDR-TB among 
new TB cases in China was the highest in Henan Province (7.8%); prevalence among re-treatment was 
highest in Inner Mongolia Province (41.9%). 
1  Caution needs to be exercised when interpreting data from Papua New Guinea because of  incompletion in recording and reporting .
2  Includes preliminary data from 2007 and 2008 .
3  Weighted prevalence based on data from provinces .
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TB-HIV co-infection: Prevalence of HIV in new TB cases in 2006 was highest in Malaysia (11.0%) and lowest 
in the Philippines (0.1%). The percentage of TB patients tested for HIV in the Region remained relatively 
low: 2.7% of the total notified cases. There was a significant increase in the use of anti-retroviral therapy 
(ART) in the Region. However, detailed and complete data as well as strong collaboration in HIV and TB 
management are needed to be able to closely monitor the use of ART in the Region by country and area.
Laboratory services: Nearly 90% of microscopy laboratories in the Region participated in an external 
quality assessment (EQA) programme. The number significantly increased from 2005 with a substantial 
uptake of the EQA programme in the Philippines. Regionally, the number of mycobacterium culture and 
drug susceptibility testing (DST) facilities in the Region had rapidly increased in 2006.
Financing TB control programme: The national TB control programme (NTP) budgets of Cambodia, China, 
the Philippines, and Viet Nam for which financial reports were available had increased during the years 
2002–2008, with a range of +11% in the Philippines to +130% in China. Routine DOTS implementation 
continued to account for the largest share of the NTP budgets in all four countries. The total cost of TB 
control in 2008 was estimated to be US$ 289 million; China accounted for 78% of the estimated total cost 
in the four countries. The estimated gap between the available funding and total cost of TB control in 
the four countries was US$ 60 million. In 2008, the total cost to treat one TB patient was estimated at 
approximately US$ 310. The total combined expenditure for TB control in 2006 from the four countries was 
US$ 175 million.
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Notified cases (DOTS + non-DOTS) Incidence and CDR
New + relapse
(WHO total).











%number rate number rate
American Samoa 65 100 4 6 3 5  6 3 69 115
Australia  20 530 97 1159 6 269 1 405 1329 595 85 45
Brunei Darussalam 382 100 202 53 128 34 15 317 140 60 91
Cambodia  14 197 100  34 660 244 19 294 136 6875  70 949  31 243 48 62
China 1 320 864 100  940 889 71 468 291 35  382 492 1 311 184  589 619 68 79
Cook Islands 14 80 1 7 0 2 1 47 0
Fiji 833 100 114 14 73 9 22 184 83 61 88
French Polynesia 259 100 69 27 24 9 28 68 31 98 78
Guam 171 100 44 26 21 12 15 64 29 69 73
Hong Kong (China) 7132 100 5356 75 1547 22 2900 4433 1995 116 78
Japan  127 953 99  25 304 20 10 159 8 9098  28 330  12 736 86 80
Kiribati 94 100 378 404 129 138 121 348 157 107 82
Lao People’s Democratic Republic 5759 100 3958 69 3041 53 457 8779 3934 44 77
Macao (China) 478 100 374 78 144 30 174 283 127 128 113
Malaysia  26 114 100  16 051 61 9414 36 4336  26 877  11 798 58 80
Marshall Islands 58 100 138 238 45 78 43 127 57 101 79
Micronesia 111 98 104 94 41 37 37 112 50 90 82
Mongolia 2605 100 5049 194 2129 82 724 4893 2201 98 97
Nauru 10 100 12 118 2 20 4 11 5 112 42
New Caledonia 238 100 48 20 9 4 22 63 28 65 32
New Zealand 4140 100 344 8 97 2 103 352 158 95 61
Niue 2 100  0 0  1  0 0
Northern Mariana Islands 82 100 51 62 15 18 32 61 28 83 54
Palau 20 100 12 59 6 30 2 10 5 116 129
Papua New Guinea 6202 40  12 620 203 1948 31 5969  15 473 6901 81 28
Philippines  86 264 100  147 305 171 85 740 99  55 964  247 740  111 468 58 77
Republic of Korea  48 050 100  37 861 79 11 513 24  18 804  42 359  19 030 83 60
Samoa 185 100 25 13 13 7 8 36 16 64 80
Singapore 4382 100 1314 30 538 12 525 1128 505 110 107
Solomon Islands 484 100 371 77 124 26 168 655 295 56 42
Tokelau 1 0  0 0  1  0 0
Tonga 100 100 18 18 14 14 3 24 11 74 127
Tuvalu 10 100 9 86 4 38 3 31 14 29 29
Vanuatu 221 100 126 57 42 19 37 128 58 98 73
Viet Nam  86 206 100  97 363 113 56 437 65  16 645  148 918  66 271 61 85
Wallis and Futuna 15     7 3   
Western Pacific Region 1 764 231 100 1 331 333   75 671 254   38  506 031 1 915 285  859 596 66 78
ss+ = sputum smear-positive; ss-= sputum smear-negative; unk. = sputum smear result unknown; est. = estimated; CDR = case detection rate; re-treat. = re-treatment; rcvd. = received
* 2006 value / 2000 value, expressed as a percentage. The 2010 goal is 50%.
Summary Table
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75 75 –   15 12 80% 2 1 50% American Samoa
12 80 2 .5 69 10 6 7 117% 1 1 100% Australia
66 71 8 .9  56 99 177% 4 11 275% Brunei Darussalam
89 93 10   806 665 83% 102 92 90% Cambodia
92 94 0 .3 10 2 271 201 74% 20 15 75% China
100 100 –  26 24 92% 3 3 100% Cook Islands
71 71 0 .3 1  38 30 79% 5 3 60% Fiji
 89 – 2  51 29 57% 6 3 50% French Polynesia
85 85 –  58 49 84% 5 6 120% Guam
74 77 – 388 8 87 64 74% 7 5 71% Hong Kong (China)
38 60 0 .4   45 29 64% 4 3 75% Japan
62 93 –  559 402 72% 64 45 70% Kiribati
85 90 1 .8  346 292 84% 28 24 86% Lao People’s Democratic Republic
93 93 – 27  87 59 68% 7 4 57% Macao (China)
69 70 11   139 125 90% 17 17 100% Malaysia
85 87 – 3  430 241 56% 47 28 60% Marshall Islands
75 80 – 2 2 171 109 64% 19 12 63% Micronesia
82 88 0 .1 250 89 285 191 67% 36 15 42% Mongolia
0 67 –  206 134 65% 21 15 71% Nauru
88 94 –  48 35 73% 5 4 80% New Caledonia
0 60 1 .3 16  11 9 82% 1 1 100% New Zealand
  –  96 85 89% 10 9 90% Niue
73 73 –  84 90 107% 6 10 167% Northern Mariana Islands
100 100 –   115 51 44% 8 4 50% Palau
57 71 4 .0  637 513 81% 59 48 81% Papua New Guinea
82 89 0 .1 424 384 554 432 78% 58 45 78% Philippines
81 83 0 .7   142 123 87% 12 10 83% Republic of Korea
91 91 –  27 25 93% 3 3 100% Samoa
83 2 .7 101 3 39 25 64% 4 2 50% Singapore
56 85 – 5  289 194 67% 32 23 72% Solomon Islands
  –  112 112 100% 12 12 100% Tokelau
73 73 –  34 34 100% 3 3 100% Tonga
100 100 –   723 504 70% 73 55 75% Tuvalu
64 81 –  87 65 75% 7 8 114% Vanuatu
90 92 5 .0  251 225 90% 24 23 96% Viet Nam
  –   103 60 58% 11 7 64% Wallis and Futuna
89 92 1.2 1298 498 261 199 76% 21 17 81% Western Pacific Region
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1 Introduction
This report is the annual report on tuberculosis (TB) control published by the World Health Organization 
(WHO), Regional Office for the Western Pacific (WPRO). Geographically and economically, the Western 
Pacific Region (the Region)—which covers East Asia and the Pacific—has great diversity of natural and 
human resources, economic dynamism, technological expertise and agricultural productivity. The Region 
has a total population of 1764 million, representing approximately 27% of the world’s population. Yet 
in 2006, the Region accounted for 21% and 24% of the estimated global TB incidence and prevalence, 
respectively.
Each year 36 countries and areas 4 in the Region report data to the WHO using a standardized data collection 
form for reporting surveillance data. Using data on disease burden and case notifications in 2006 and 
treatment outcomes of patients registered for treatment in 2005, this report presents an assessment of TB 
epidemiology, burden, estimation and progress towards the Regional goals to halve the prevalence and 
mortality rates by 2010 from 2000 level. 5 The outcome targets are detection of at least 70% of new smear-
positive cases and successful treatment at least 85% of cases that are detected. This report includes data 
on drug resistance, 6 TB-human immunodeficiency virus (HIV) surveillance, and laboratory services within 
the Region. Furthermore, the report presents financial data, and discusses financing of national TB control 
programmes (NTPs), and availability and sources of funds. The report also highlights the funding gaps 
for such financing between 2002 and 2008 for four countries with a high burden of TB for which detailed 
financial data were available. Expenditures for TB control in 2006 are also discussed.
In addition, the report provides country and area-specific data, which include epidemiologic indicators 
and detailed estimation of prevalence and mortality towards the 2010 goals for seven countries with a 
high burden of TB. There are eight annexes. The first four describe methods for estimation of prevalence, 
mortality, and numbers of multidrug-resistant TB 7 (MDR-TB) cases, and provide definitions and the formulas 
used to derive estimates. Annex 5 is explanatory notes for the tables listed in Annex 6. Estimated numbers 
of MDR-TB cases that had occurred in 2006 and notified prevalence of resistance to anti-TB drugs may be 
found in Annexes 7 and 8, respectively.
4  See Table 1 for countries and areas in the region .
5  The Regional goals differ from the Millennium Development Goals .
6  Including preliminary data for 2007 and 2008 .
7  Isolate resists to at least isoniazid and rifampicin .
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2 Epidemiology
2.1  Estimated burden
Figure 1 shows the prevalence and incidence rates of all forms of TB by country and area in the Region. 
In 2006, there were over 3.5 million prevalent TB cases (199 per 100 000 population). Over 1.9 million of 
these were new cases (109 per 100 000 population), including 0.9 million new smear-positive cases 
(49 per 100 000 population). The incidence rate was highest in Cambodia (500 per 100 000 population) 
and lowest in Australia (6 per 100 000 population). Cases from Cambodia, China, the Philippines, and 
Viet Nam together accounted for 93% of all incidence cases in the Region (Figure 2). Prevalence changed 
at an estimated rate of -4.9% annually since 2000 and at a rate of -3.4% from 2005 (Table 2).
FIGuRE 1: Incidence (left) and prevalence (right) rates of all forms of TB by country and area, 2006 
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Death from TB occurred in approximately 0.3 million cases in 2006 (17 per 100 000 population). The 
mortality rate was highest in Cambodia (92 per 100 000 population) and lowest in American Samoa, 
Australia, and New Zealand (1 per 100 0000 population). Deaths from TB in China, the Philippines, and 
Viet Nam accounted for 89% of all TB mortality in the Region. The regional TB mortality rate declined at an 
estimated rate of -3.7% annually since 2000; however, it did not change compared to 2005 (Table 2).  
TABLE 2:  Estimated prevalence (all forms of TB) and TB mortality rates per 100 000 population in the Region, 2006
Estimated prevalence rate* Overall change (%) Annual rate of change since 
2000,  
% (95% CI)2000 2006 From 2000 From 2005
Prevalence 261 199 -24 -3 -4 .9 (-5 .8 to -4 .0)
mortality 20 17 -15 0 -3 .7 (-4 .7 to -2 .9)
CI = confidence interval; *rates are per 100 000 population
2.2  Trend of prevalence and TB mortality rates towards goals in 2010
Accelerated efforts are needed in order to achieve the 2010 regional goals. Regionally, prevalence and 
mortality had declined at rates of -4.9% per year [95% confidence interval (95% CI), -5.8% to -4.0%] and 
-3.7% per year (95% CI, -4.7% to -2.9%) respectively, since 2000. At the current rate of decline, in 2010 the 
prevalence would be 163 (95% CI, 152 to 176) and 14 TB deaths (95% CI, 13 to 15) per 100 000 population 
would occur (see the estimation method in Annex 1) (Table 3). 
TABLE 3:  Estimated TB prevalence and mortality rates in 2010 by countries with a high burden of TB in the Region, and Regional 2010 
goals 
Country
Prevalence rate Mortality rate








Cambodia -1 .6% 635 403 -4 .4% 74 51
China -3 .2% 184 136 -4 .7% 13 10
Lao People’s Democratic Republic -2 .6% 267 173 -3 .7% 20 14
Mongolia -6 .2% 147 143 -12 .3% 11 18
Papua New Guinea -5 .2% 377 319 -4 .6% 37 30
Philippines -3 .9% 366 277 -4 .0% 38 29
Viet Nam -1 .5% 213 126 -1 .1% 22 12
Western Pacific Region -4.9% 163 131 -3.7% 14 11
a Average from 2000 through 2006
*Per 100 000 population, assuming current rate of change
† Per 100 000 population
2.3 Case notification and trends
Approximately 1.3 million cases of all forms of TB were notified in 2006 (75 per 100 000 population), 
corresponding to 25% of the total cases notified globally. There were 0.7 million smear-positive cases 
notified in 2006 (38 per 100 000 population), corresponding to 27% of the total smear-positive cases 
notified globally. The largest number of smear-positive cases was reported from China (0.5 million), 
followed by the Philippines (0.09 million) and Viet Nam (0.06 million). Together with Cambodia, cases from 
these four countries accounted for 93% of all cases notified in the Region. Figure 3 shows case notification 
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rates for all forms of TB in countries and areas in the Western Pacific Region and neighbouring countries 
and areas in 2006. Two countries with a high burden of TB in the Region, Cambodia and Papua New Guinea, 
had case notification rates of ≥200 per 100 000 population.
FIGuRE 3:  Case notification rates (all forms of TB) per 100 000 population in countries and areas in the Western Pacific Region and 
neighbouring countries and areas, 2006
The boundaries shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal 
status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.  
White lines on maps represent approximate border lines for which there may not yet be full agreement. 
 WHO 2005. All rights reserved
Since 2002, the case notification rates in the Region have steadily increased from 47 to 75 per 100 000 
population in all forms of TB (trend +11.8% per year; 95% CI, +5.4% to +18.2%) and from 22 to 38 per 
100 000 population in new smear-positive TB cases (trend +14.7% per year; 95% CI, +6.9% to +22.5%). 
Compared to 2005 however, the case notification rate in new smear-positive cases in 2006 was relatively 
unchanged (Figure 4).
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Figure 5 shows age and sex-specific case notification rates (new smear-positive) for seven countries with 
a high burden of TB in the Region. In general, TB disproportionately affected males and older persons. For 
every female smear-positive TB case younger than 15 years of age, 1.5 to 2.8 male smear-positive TB cases 
were notified. In some countries such as Mongolia and Papua New Guinea, a different epidemiological 
pattern was observed: TB more frequently occurred in young adults. 
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The distribution of sex ratio of notified sputum smear-positive cases by age group showed extremely 
different patterns from Cambodia to Viet Nam (Figure 6). Various factors may have contributed to the 
differing age and sex patterns of TB between Cambodia and Viet Nam. These factors include, though are 
not limited to: the Khmer Rouge regime in Cambodia which decimated a large proportion of the total 
population from 1975–79; the ensuing internal conflicts during the 1980s taking the lives of probably 
more males than females; and more recently, differences in the spread of the HIV epidemic between the 
two countries. Women in Cambodia may be more likely to seek health care than men, particularly if they 
have respiratory symptoms. Cambodian men may put off seeking health care and thus their TB diagnoses 
may be more delayed than women. The national TB prevalence survey 8 conducted in 2002 in Cambodia 
demonstrated that the prevalence of sputum smear-positive TB was 2.6 times as high in men as in women 
age ten years or older. In addition, in Viet Nam, migration may have affected more men than women in 
economically-productive age groups.
2.3.1 Trends of average age of TB cases
Trends in the age of TB cases reflect underlying epidemiological processes of TB infection. Stable or 
declining average age of overall TB patients is an indicator of on-going transmission in the population. 
With low or no ongoing transmission in a population, new cases of TB will largely occur among the already 
infected, and their average age will increase by at least one year annually. However, if new TB infections 
still occur among a population, the average age of TB patients from the population will be stable or even 
decline. 
Figure 7 shows that in Cambodia, China, Japan, and Viet Nam the average age of notified TB patients 
within the age group of 55 years or older is rising, while the average age of reported TB cases within the 
younger age group is decreasing in Japan (males only), Cambodia (females only), and China and Viet Nam 
(both males and females). The spread of HIV infection is one possible reason for the shift towards younger 
adults in some countries. Another possible explanation is migrant populations from places with a high 
burden of TB. For example, in Japan about 20% of TB patients age 15–34 are foreign nationals. Likewise, in 
Brunei Darussalam, the epidemiology of TB is heavily influenced by TB in migrants. Internal migration may 
play a role in China and in Viet Nam, where young mobile adults from rural areas seek jobs in cities. In the 
Republic of Korea, by contrast, the TB patient is getting older in both age classes. 
FIGuRE 7:  Trend of average age of males and females with sputum smear-positive TB, 2000–2006
A.  Countries with a high burden of TB 
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Figure 8 shows age and sex-specific changes in case notification in the period 2000–2006. The notification 
rate significantly increased in certain age groups in the Lao People’s Democratic Republic (ages 25–44 
and 55–64 in males) and in the Philippines (age 15–64 in both males and females), while it declined in 
Viet Nam (ages 35–44 and 55–64 in females). Some of the changes reflect increases in case detection 
efforts, particularly in countries with a high burden of TB, e.g., China and the Philippines. In Viet Nam, 
declines in notification rates in older age-groups, particularly in females, were offset by increases in the 
15–34 year age group, probably partly in relation to increases in HIV-related TB. 
FIGuRE 8:  Annual average rate of change in notification rate by age group in selected countries and areas in the Region, 2000–2006
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Vertical lines represent 95% confidence intervals.
B.  Countries and areas with an intermediate burden of TB
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Vertical lines represent 95% confidence intervals .
In Brunei Darussalam, Macao (China), and Singapore, certain age groups are not shown because the number of cases in those groups are small, zero case 
was reported in a year or so, and therefore 95% confidence intervals are too wide . 
2.4 DOTS coverage, case detection, and trends
Overall, directly observed treatment, short-course (DOTS) coverage in the Region was 99.7% in 2006. Thirty 
countries and areas, including six countries with a high burden of TB, had reached 100% coverage. The 
coverage is less than 50% in Papua New Guinea, while in some countries DOTS coverage is less than 100% 
due to reporting errors.
In 2005, the Region reached the global and regional target of detecting 70% of the estimated new 
sputum-positive TB cases and has sustained high case detection rates since then (Figure 9). In 2006, 
23 countries and areas in the Region, including five countries with a high burden of TB—China, the 
Lao People’s Democratic Republic, Mongolia, the Philippines, and Viet Nam—have reached the target. A 
substantial improvement in case detection rates was reported from the Lao People’s Democratic Republic 
(+17%) and Mongolia (+18%). The target of 70% case detection rate was reached for the first time for the 
Lao People’s Democratic Republic (Table 4).
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FIGuRE 9:  Trends in DOTS coverage and case detection in smear-positive cases in the Region, 1995–2006
DOTS, directly observed treatment, short-course 
DOTS case detection rate was calculated by dividing annual new smear-positive notifications under DOTS with estimated annual new smear-positive 
incidence .




Case detection rates (%)
DOTS area
% change 
DOTS + non-DOTS area*
% change2005 2006 2005 2006
Cambodia 100 66 62 -6
China 100 80 79 -1
Lao People’s Democratic Republic 100 68 77 13
Mongolia 100 82 97 18
Papua New Guinea 40 21 21 0 28 28 0
Philippines 100 75 77 3
Viet Nam 100 84 85 1
Western Pacific Region 99.7 76 77 -1 78 78 0
* Countries with 100% DOTS coverage have no non-DOTS area by definition; the figures match the left column. 
2.5 Drug resistance
From 2000 through 2008, 18 countries and areas in the Region have conducted at least one round of 
drug-resistance surveillance (DRS) and reported the results to the Global Project on Anti-tuberculosis 
Drug Resistance Surveillance, which was launched in 1994. New survey data from Australia, Mongolia, 
New Zealand, and Northern Mariana Islands have become available in this report. TB strains resistant to 
any of the first-line anti-TB drugs were found in all settings surveyed in the Region. Prevalence of MDR-
TB varied from country to country and by treatment history of the patient. (See Table 5, Figure 10 and 
Annex 8.) Among new TB cases in the Region, the prevalence ranged from 0% in Cambodia to 11.1% in 
Northern Mariana Islands. MDR-TB prevalence in re-treatment cases ranged from 1% in Singapore to 27.5% 
in Mongolia. In five countries with a high burden of TB for which surveyed data were available (Cambodia, 
China, Mongolia, the Philippines, and Viet Nam), MDR-TB prevalence in new cases ranged from 0% in 
Cambodia to 4.9% in China (weighted prevalence based on data from the provinces), and in re-treatment 
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Notably, data from recent DRS in five of China’s 31 provinces had revealed alarming rates of MDR-TB in more 
than half of these provinces (Figure 10). In these provinces, the rate of MDR-TB in new TB cases ranged from 
2% to 10%, substantially higher than the global average. MDR-TB rate was greater than 7% among new TB 
cases in three provinces—Henan, Heilongjiang, and Inner Mongolia—that had implemented a successful 
DOTS programme for nearly ten years, indicating that implementing DOTS alone may not be sufficient to 
control the spread of the MDR-TB epidemic in China.
TABLE 5:  Anti-TB drug resistance in recent surveys, by country and area, 2005–2008 (see Annex 8 for more detailed data)
Country and area Year
New cases Re-treatment cases












Australia* 2005 808 8 .8 10 .1 1 .5 - -
Fiji* 2006 38 0 .0 0 .0 0 .0 - -
Mongolia† 2008 650 - 16 .6 1 .4 200 27 .5
New Caledonia* 2005 5 20 .0 20 .0 0 .0 - -
New Zealand† 2007 211 4 .7 9 .0 0 14 14 .3
Northern Mariana Islands 2006 18 16 .7 22 .2 11 .1 - -
Vanuatu 2006 29 3 .4 3 .4 0 - -
Viet Nam 2006 1619 19 .1 30 .7 2 .7 207 19 .3
# = number; INH = isoniazid; MDR-TB = multidrug-resistance tuberculosis
*Combined new and re-treatment cases.
†Preliminary results, some data were not yet available.
FIGuRE 10:  Geographical distribution of proportion of MDR-TB among new (left) and re-treatment (right) TB cases by country and area 
in the Region and by province in China, 2000–2006*
*In the left map, the data from Australia, Fiji, Guam, New Caledonia, and Solomon Islands indicate new and re-treatment cases combined . Only data on 
new cases are available for Northern Mariana Islands and Vanuatu . 
The boundaries shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal 
status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.  
©WHO 2005. All rights reserved
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Figure 11 shows the proportions of MDR-TB cases in new and re-treatment cases estimated to have 
occurred by country and area in 2006 (see Annex 2 for estimation method). Globally, the Region had the 
highest number of estimated MDR-TB cases compared to other WHO regions. Regionally, a total of 152 694 
MDR-TB cases (95% CI, 119 886 to 188 014) were estimated to have occurred in 2006 (see Annex 8).
Among new TB cases, it was estimated that 82 087 MDR-TB cases (95% CI, 57 531 to 107 804) had occurred 
among 1 882 930 new TB cases in the Region in 2006. The proportion of MDR-TB in new TB cases was 
estimated to be 4.4% (95% CI, 3.9% to 4.8%). MDR-TB cases from China, the Philippines, and Viet Nam 
accounted for 97% of the total MDR-TB cases among new TB cases.
For re-treatment cases, a total of 70 601 MDR-TB cases (95% CI, 47 134 to 94 543) were estimated to have 
occurred among 289 214 re-treatment cases in 2006 (24.4%; 95% CI, 22.7% to 26.1%). The proportion of 
MDR-TB in re-treatment cases was estimated to be 24.4% (95% CI, 22.7% to 26.1%). Cases from China, the 
Philippines, and Viet Nam accounted for 98% of the total estimated cases among re-treatment cases. 
Based on the overall case management data in 2006, however, 6331 new patients and 1298 re-treatment 
patients were reported with available drug susceptibility testing (DST) results in the Region. Of those, 
89 (1.0%) and 498 (38.4%) had MDR-TB, respectively. These numbers contrast sharply with the estimated 
numbers of MDR-TB cases in the Region discussed earlier. Capacity to detect and treat MDR-TB cases 
needs to be scaled up rapidly in the Region, particularly in the countries and areas reported to have high 
prevalence of MDR-TB. Prevalence of MDR-TB among routinely tested cases was high in the Philippines 
(57.6% in new cases and 90.6% in re-treatment cases), likely because DST was performed in the cases most 
at risk of MDR-TB. 
FIGuRE 11: Percentage of MDR-TB among new (left) and re-treatment (right) cases in countries and areas with a high burden of TB, 
2006
MDR-TB = multidrug-resistant TB
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2.6 TB-HIV
2.6.1 Estimated prevalence of HIV among new TB cases
HIV infection fuels the TB epidemic, particularly in countries and areas with a high burden of TB, because 
it reduces cell-mediated immunity and is a powerful risk factor for the development of TB. The annual risk 
of developing active TB disease in a co-infected person ranges from 5% to 15%, depending on the degree 
of immune suppression. In the past 10–15 years, TB case numbers have increased by 300–400% in high 
HIV-prevalent countries of Africa. To a lesser extent, TB-HIV co-infection also affects some countries and 
areas in the Region. 
Two countries in the Region, Cambodia and Papua New Guinea, had a generalized HIV epidemic (HIV 
prevalence >1% of pregnant women) until year 2005. The prevalence of HIV in Cambodia is now below 
1% in adults age 15-49 years. The prevalence of HIV in new TB cases in 2006 was estimated to be the 
highest in Malaysia (11.0%), followed by Cambodia (9.6%), Brunei Darussalam (8.9%), Viet Nam (5%), and 
Papua New Guinea (4.0%). 9 The prevalence was the lowest in Mongolia and the Philippines (0.1%) (Table 6).
TABLE 6: Estimated prevalence of HIV in new TB cases in selected countries in the Region, 2006
Country Prevalence of HIV in new TB cases* (%)
Malaysia 11 .0
Cambodia 9 .6
Brunei Darussalam 8 .9
Viet Nam 5 .0
Papua New Guinea 4 .0




*For Cambodia, the Lao People’s Democratic Republic, Malaysia, and Viet Nam direct estimation method was used 
for estimation based on surveillance data. Estimates may not be compared to figures published in the Global TB 
Control Report 2008 due to changes in estimation methods.
In all countries and areas in the Region, HIV prevalence in new TB cases is consistently higher than the 
prevalence of HIV in the general population (Figure 12). In Malaysia, HIV and TB cases share important risk 
factors and the two epidemics are highly concentrated in similar populations (i.e., injecting drug users 
[IDUs]). 
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9  For Cambodia, the Lao People’s Democratic Republic, Malaysia, and Viet Nam direct estimation method was used for estimation based on surveillance data . 
Estimates should not be compared to figures published in the Global TB Control Report 2008 due to changes in estimation methods . 
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2.6.2 Surveillance on HIV in TB cases
In some areas in Papua New Guinea, the prevalence of HIV among TB patients was considerably higher 
than previously estimated; data from sentinel surveillance centres in three major health facilities in 
Port Moresby, Goroka, and Lae showed that 12% to 19% of TB cases were HIV-infected in 2003. 10
In Cambodia, HIV prevalence has fallen to an estimated 0.9% among the adult population in 2006, down 
from a peak of 2.0% in 1998. Three national surveys of HIV prevalence in TB patients showed a significant 
decline, from 11.8% in 2003 to 9.9% in 2005 to 7.8% in 2006.
The HIV epidemic is still at the concentrated stage in other countries and areas in the Region, particularly in 
China and Viet Nam. The average HIV prevalence in drug users in selected sentinel sites in China was 7.5% 
in 2005, while that of the general population was estimated to be about 0.05%. There are also geographic 
variations: the HIV prevalence in IDUs in 2006 was greater than 10.0% in selected sites in Xinjiang, 
Henan, Sichuan, Guangxi, and Guizhou. 11 The routine surveillance data from China showed 1.3% of TB 
cases tested positive for HIV in 2006 (Table 7). However, because only 0.14% of all the TB cases notified in 
2006 were tested, and these primarily from areas of higher HIV prevalence, the estimate is unlikely to be 
representative.
In Viet Nam, the estimated proportion of adults age 15–49 living with HIV had slightly increased from 2003 
to 2005, from 0.4% to 0.5%. The main risk factors associated with HIV infection are the use of contaminated 
injecting equipment and unprotected sex with casual partners or sex workers. The prevalence of HIV 
infection varies across provinces even among IDUs, who are one of the highest risk groups, from 4.0% in 
Dong Thap Province to 36.1% in Lai Chau Province. 12 Surveillance data from 2006 showed that 15.0% of the 
notified TB cases were tested and 5.0% of them turned out to be TB-HIV co-infected. In Ho Chi Minh City, 
the prevalence had significantly increased from 1.5% in 1997-1998 to 9.0% in 2001–2002. 13 The prevalence 
remains high at 7.7% in selected districts of Ho Chi Minh City in 2006–2007. 14
TABLE 7:  Surveillance data on HIV in TB cases in selected countries in the Region, 2006 
Country
TB cases notified (new and 
relapse) Tested for HIV Positive for HIV
HIV-positive 
among TB (%)
Cambodia* 34 660 3547 342 9 .6
China 940 889 1350 18 1 .3
Malaysia 16 051 13 039 1438 11 .0
Viet Nam 97 363 14 230 708 5 .0
Western Pacific Region 1 331 333 38 672 2632 6.8
*Cambodia made great progress in testing TB cases for HIV in 2007.
10  National Department of Health, Papua New Guinea, 2006 .
11  Sun X et al. The development of HIV/AIDS surveillance in China . AIDS, 2007:21:S33-S38
12  Tuang et al . Human immunodeficiency virus (HIV) infection patterns and risk behaviours in different population groups and provinces in Viet Nam . Bulletin of the 
WHO, 2007:85:35-41 .
13  Tran NB et al. HIV and tuberculosis in Ho Chi Minh City, Viet Nam, 1997-2002 . Emerging Infectious Diseases, 2007:13:1463-1469 .
14  Data presented at the Meeting on the Revised TB-HIV Co-Infection Framework for the Western Pacific Region held in February 2008 .
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The overall percentage of TB patients tested for HIV in the Region remained too low: 2.7% of the total 
notified cases (Figure 13). Across the 17 reporting countries and areas, HIV testing of 38 672 TB patients led 
to the identification of 2632 HIV positive cases, representing 6.8% of the total tested cases (Table 7) and 
12.0% of the estimated burden of incident TB-HIV.



















WPR = Western Pacific Region.
2.6.3 Anti-retroviral therapy, co-trimoxazole prophylaxis, screening of TB for people living with HIV, 
and isoniazid prophylaxis
The use of anti-retroviral therapy (ART) has expanded in the past four years in the Region. The number of 
people living with HIV/AIDS (PLWHA) on ART increased from 16 170 in 2004 to 83 621 in 2007. Cambodia, 
China, Malaysia, Papua New Guinea, and Viet Nam are countries that have more than 1000 PLWHA on ART 
in 2007.
ART should significantly improve the long-term survival rate for TB-HIV co-infected cases. A report from 
Thailand highlighted that the survival rate at one, two, and three years after TB diagnosis were 96, 94, and 
88%, respectively for TB-HIV patients on ART, and 44, 19, and 9%, respectively for those not on ART. 15
Co-trimoxazole (CTX) preventive therapy (CPT) may improve TB treatment outcomes in TB-HIV co-infected 
cases. A report from An Giang, Viet Nam showed that patients who were not on CPT during the course of 
TB treatment were ten times as likely to have unsuccessful outcomes (i.e., failure, death, or default) as those 
who were on CPT. 16
In 2005 and 2006 there was a significant increase in the use of CPT and ART in the Region (p-value<0.01 for 
both). However, detailed and complete data as well as strong collaboration in HIV and TB management are 
needed to be able to closely monitor the use of CPT and ART in the Region. 
As noted earlier, PLWHA are more likely to develop TB disease during their lifetime and this fact emphasizes 
the importance of TB screenings for PLWHA. Reports from Cambodia 17, 18 and Viet Nam 19 showed that 24% 
to 43% of PLWHA turned out to have had TB disease at the first screening. TB screenings for PLWHA yields 
much higher probability of finding new TB cases than screenings for any other population.
15  Manosuthi W et al . Survival rate and risk factors of mortality among HIV/TB-coinfected patients with and without antiretroviral therapy . Journal of Acquired Immune 
Deficiency Syndromes, 2006:43:42-6 . 
16  Thuy TT et al . HIV-associated TB in An Giang Province, Viet Nam, 2001-4: Epidemiology and TB treatment outcomes . Public Library of Science, 2007:2:e507 .
17  Cain KP et al . The epidemiology of HIV-associated tuberculosis in rural Cambodia . International Journal of Tuberculosis and Lung Disease, 2007:11:1008-13 .
18  Kong BN et al . Opportunistic infections and HIV clinical disease stage among patients presenting for care in Phnom Penh, Cambodia . Southeast Asian of Tropical 
Medicine and Public Health, 2007:38:62-68 .
19  Klotz SA et al . Clinical features of HIV/AIDS patients presenting to an inner city clinic in Ho Chi Minh City, Viet Nam . International Journal of STD & AIDS, 2007:18:482-
485 .
 Tuberculosis Control in the Western Pacific : 2008 Report 19
2 | EPIDEMIOLOGY
For patients in whom TB is excluded, isoniazid preventive therapy (IPT) may be warranted. IPT is a six-
month course of daily isoniazid which is given to PLWHA with latent TB infection in order to prevent the 
development of active TB disease. IPT has been shown to decrease TB incidence among PLWHA with latent 
TB infection by up to 60%.
Although the effectiveness of IPT for latent TB infection is established, implementation remains very low. IPT 
is implemented in Cambodia and China, and is partially implemented in Mongolia and Papua New Guinea; 
however, uptake remains low. Small-scale pilot projects providing IPT are implemented in Viet Nam.
2.6.4 Regional TB-HIV framework
To facilitate collaborative TB-HIV activities with the aim to reduce TB transmission and decrease the 
morbidity and mortality associated with TB-HIV, WHO/WPRO, in collaboration with experts on TB and HIV/
AIDS, developed a regional framework for TB-HIV, published in 2004. The framework has been revised with 
the aim of (1) introducing new approaches to improve HIV-testing rates among TB patients through the 
implementation of provider-initiated testing and counselling (PITC), and to improve TB screening rates 
among PLWHA in the Region, and (2) scaling up TB infection control measures to prevent transmission of 
the disease within health facilities, such as TB clinics and HIV/AIDS clinics. The revised framework will be 
published in mid-2008.
2.6.5 Risk factors for increased case fatality rate 
Higher case fatality rates were observed in places in which the prevalence of HIV among TB patients was 
high, as well as in ageing populations (Figure 14). Case fatality rates of over 20% in TB-HIV cases have 
been reported from various areas in the Region, likely due to their late diagnosis which made patients 
vulnerable not only to TB but also to other opportunistic infections such as candidiasis and Pneumocystis 
jiroveci infection. A report from Malaysia showed that the median CD4+ T-lymphocyte cell count of TB-HIV 
co-infected cases at diagnosis ranged from 44 to 58 cells/µL,  20 much lower than that observed in sub-
Saharan Africa (186–393 cells/mm3).
In places in which the epidemic of TB is mature and most TB cases occur in elderly people, such as Japan 
and Singapore, case fatality rates are more than 10%, while HIV prevalence is low.
FIGuRE 14:  Case fatality rates against prevalence of HIV in TB cases in some countries with high and intermediate burdens of TB in the 
Region, 2006
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Circle’s size is proportional to percentage of smear-positive TB cases age >65 years .
20  Nissapatorn V et al . Tuberculosis in HIV/AIDS patients: A Malaysian experience . Southeast Asian Journal of Tropical Medicine and Public Health, 2005:36:946-53 .
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HIV and MDR-TB co-infection is a serious concern in places where prevalence of MDR-TB among new TB 
cases is high. A cohort study in Ho Chi Minh City, Viet Nam, showed that HIV and MDR-TB independently 
affected sputum smear-positive patients; 21 those with HIV were 30 times as likely to die during TB treatment 
as those without HIV, while those with MDR-TB were 4.7 times as likely to die as those with susceptible TB. 22 
Another report from Thailand showed an even more alarming finding: HIV-infected persons with MDR-TB 
were 12 times as likely to die as those with drug-susceptible TB. 23
21  Thuy TT et al . HIV-associated TB in An Giang Province, Viet Nam, 2001-4: Epidemiology and TB treatment outcomes . Public Library of Science, 2007:2:e507 .
22  Quy HT et al . Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Viet Nam . International Journal of Tuberculosis 
and Lung Disease, 2006:10:45-51 .
23  Sungkanuparph S et al . Impact of drug-resistant tuberculosis on the survival of HIV-infected patients . International Journal of Tuberculosis and Lung Disease, 
2007:11:325-30 .
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3 Treatment outcomes
The Region continued to observe treatment success rates beyond the target of 85%. Of 0.7 million new 
pulmonary smear-positive cases registered for treatment in DOTS areas in the 2005, treatment success was 
remarkably high, reporting at 92% overall. Across the Region, 20 countries and areas had reached the 85% 
treatment success target. Among the countries with a high burden of TB, the treatment success rate was 
highest in China (94%), followed by Cambodia (93%) and Viet Nam (92%). The treatment success rate of 
Papua New Guinea improved from 65% in 2004 to 71% in the 2005 cohort (Figure 15).
FIGuRE 15:  Treatment outcomes for new smear-positive cases registered in 2005 in DOTS areas in countries with a high burden of TB in 
the Region 
DOTS:  directly observed treatment, short-course; 
Numbers in bars are treatment success rates .
Overall, unfavourable treatment outcomes of 8% and 13% were reported from the 2005 cohorts of new 
smear-positive cases and re-treatment smear-positive cases, respectively, and their breakdowns are shown 
in Figure 16. At least a quarter of unfavourable outcomes were attributable to non-evaluated cases in both 
cohorts, which was higher than those reported in earlier years. It should be noted that the cases reported 
under the category “transfer-out” can have any of the other treatment outcomes, but detailed information 
is simply not available, as outcomes are not recorded in the TB registers.
FIGuRE 16:  Unfavourable outcomes among new smear-positive cases and re-treatment smear-positive cases registered in 2005 in DOTS 
areas in the Region
Number in each segment indicates the respective proportion of treatment outcome .
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4 TB laboratory services
4.1 Laboratory capacity
TABLE 8:  External quality assessment of sputum smear microscopy in countries with a high burden of TB in the Region, 
2006
Country
# of smear micros-
copy laboratories
Labs included in 
EQA (%)
% change from 
2005
# of labs with 
unsatisfactory 
result* (%)
Labs in which 
necessary correc-
tive actions were 
taken (%)
Cambodia 186 100 0 24 100
China 3010 92 2 4 100
Lao People’s Democratic Republic 155 87 -12 4 .4 67
Mongolia 36 100 0 8 100
Papua New Guinea 60 25 213 6 25
Philippines 2374 100 285 9 100
Viet Nam 874 85 -15 9 -
EQA = external quality assessment; # = number; labs = laboratories; - = no data
*Definitions of unsatisfactory results may vary slightly between countries and areas. For example, in the blind slide rechecking, which is one of the three components of EQA, either one 
major error (i.e., high false positive or negative) or three quantitative minor errors may be considered unsatisfactory and require immediate corrective actions.
The data were presented at the 2nd Laboratory Training Course for Asia-Pacific held in Ha Noi, Viet Nam in September 2007.
Across the Region, there are 7390 TB laboratories performing acid-fast bacilli smear microscopy; 6433 (87%) 
of which participated in external quality assessment (EQA) programmes. In six countries out of seven with 
a high burden of TB—Cambodia, China, the Lao People’s Democratic Republic, Mongolia, the Philippines, 
and Viet Nam—over 85 % of sputum smear microscopy centres participated in EQA activities, and in four 
countries out of the six—Cambodia, China, Mongolia, and the Philippines—100% of the laboratories with 
unsatisfactory results in EQA received corrective actions (Tables 8). Between 2005 and 2006, the number 
of laboratories participating in EQA programmes increased significantly, from 5 to 15 laboratories in 
Papua New Guinea and from 491 to 2374 laboratories in the Philippines.
Of the 7390, a total of 458 and 122 laboratories were capable for mycobacterium bacilli culture and for 
DST of anti-TB drugs, respectively. Of these, 360 and 90, respectively, were located in China (Table 9). In 
Cambodia, China, Mongolia, the Philippines and Viet Nam, mycobacterium culture facilities that are 
performing DST have been established. However, overall in the Region, the number of laboratories capable 
of doing culture and DST is insufficient given the threat of MDR-TB and TB-HIV co-infection and given the 
need to detect and treat cases under those conditions.
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Cambodia 14 197 186 1 .3 0 3 1 .1 0 1 0 .7 0
China 1 320 864 3010 0 .2 0 360 1 .4 180 90 0 .7 75
Lao People’s Democratic Republic 5759 155 2 .7 4 0 0 .0 0 0 0 .0 0
Mongolia 2605 36 1 .4 8 1 1 .9 -5 1 3 .8 -5
Papua New Guinea 6202 60 1 .0 0 1 0 .8 0 1 1 .6 n/a*
Philippines 86 264 2374 2 .8 27 3 0 .2 0 3 0 .3 -25
Viet Nam 86 206 874 1 .0 11 18 1 .0 -44 2 0 .2 0
# = number; labs = laboratories; pop = population; DST = drug susceptibility testing; mil =million 
To provide culture for diagnosis of paediatric, extrapulmonary and smear-negative HIV-infected TB cases, as well as DST for re-treatment and failure cases, most countries and areas 
will need one culture facility per five million population and one DST facility per ten million population. However, for countries and areas with large populations, one laboratory for 
culture and DST in each major administrative area (e.g., province) may be sufficient.
*There was no DST facility in Papua New Guinea in 2005.
4.2 Supranational reference laboratory network
A network of laboratories was developed in conjunction with the Global Project on Anti-tuberculosis 
Drug Resistance Surveillance (see section 2.5 Drug resistance) and named the Supranational Reference 
Laboratory Network (SRLN). The SRLN participates in annual proficiency testing and has a mandate to 
assist national reference laboratories in laboratory assessments: in proficiency testing, quality assurance of 
results from drug resistance surveys, and other technical guidance as necessary. There are six supranational 
reference laboratories in the Region (Table 10).
TABLE 10:  Supranational reference laboratories in the Region and countries and areas to which they provide support
Supranational reference laboratory Countries and areas
Institute of Medical and Veterinary Science (IMVS), Adelaide, Australia Viet Nam, Pacific island countries and areas
Korean Institute of Tuberculosis (KIT), Seoul, Republic of Korea The Philippines
Queensland Mycobacterium Reference Laboratory (QMRL), Brisbane, Australia Papua New Guinea, Pacific island countries and areas
Research Institute of Tuberculosis (RIT), Tokyo, Japan Cambodia, Mongolia, the Philippines
Tuberculosis Reference Laboratory, Department of Health, Hong Kong, China China, Lao People’s Democratic Republic
The Centres for Disease Control and Prevention (CDC), Atlanta, USA, through 
Diagnostic Laboratory Services, Inc .*, Hawaii, USA
American Samoa, Guam,  
Northern Mariana Islands, Marshall Islands, Micronesia, Palau
*Not a member of the Supranational Reference Laboratory Network (SRLN)
In the Pacific island countries and areas, a TB laboratory network has been put in place since 2004, in 
collaboration with the Institute of Medical and Veterinary Science, Adelaide, Australia; the Queensland 
Mycobacterium Reference Laboratory, Brisbane, Australia; the Pacific Paramedical Training Centre (PPTC) 
in Wellington, New Zealand; the Secretariat of the Pacific Community (SPC);  US Centers for Disease 
Control and Prevention and WHO. The network is called the Pacific TB Laboratory (PaTLab) Initiative. 
The primary objectives of the PaTLab are to improve the quality of sputum microscopy by application 
of EQA, and to expand surveillance for TB drug resistance. PaTLab coordinates EQA of sputum smear 
microscopy, including panel testing, blinded slide rechecking, and onsite visits. The PaTLab has initiated 
drug resistance surveys in some Pacific island countries and areas, as described in Section 2.5. PaTLab has 
contributed significantly to the quality improvement of TB laboratory services in Pacific island countries 
and areas.
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5 Financing TB control programmes
5.1  NTP budgets and estimated total costs for TB control, 2002-2008
Thirty countries and areas in the Region provided financial reports. None of the seven countries with a 
high burden of TB is a high-income country. 24 The four countries with a high burden of TB—Cambodia, 
China, the Philippines, and Viet Nam—that provided financial reports accounted for 92% of the regional 
burden of TB. NTP budgets in these four countries have increased during the years 2002–2008 with a 
range of +11% in the Philippines to a striking +130% in China. The extraordinary budgetary increase in 
China came from additional domestic funding. By contrast, the increasing funds in the Philippines and 
Viet Nam came primarily from the Global Fund to Fight AIDS, Tuberculosis, and Malaria (the Global Fund). 
The relatively small increase in funding in the Philippines (+11%) and Viet Nam (+27%) reflect the fact that 
both countries had achieved or were close to achieving the global targets for TB control in 2002. In 2008, 
local governments will provide US$ 155 million (58%) of the required NTP funding in the four countries, 
donor agencies will fund US$ 40 million (15%), and US$ 13 million (5%) will be loans (Figure 17). China was 
the only country or area reporting taking loans to fill its budget needs. This left a reported funding gap of 
US$ 60 million in total for the four countries (22%). In absolute terms, the largest funding gap was reported 
by China (US$53 million, 88% of the total reported gap of all four countries and 24% of the total budget 
required by the Chinese NTP). Proportionately, the largest gap was in Cambodia (US$ 5 million, 53% of the 
required Cambodian NTP budget).
Notably, NTP budgets did not include costs associated with general health service and staff. For the four 
countries, the total cost of TB control in 2008 was estimated to be US$ 289 million (US$ 11 million for 
Cambodia, US$ 225 million for China, US$ 28 million for the Philippines, and US$ 25 million for Viet Nam). 
In 2008, TB control in China accounted for 78% of the estimated total cost in the four countries mentioned. 
DOTS implementation continued to account for the largest share of the NTP budgets in all four countries. 
The estimated gap between available funding and the total cost of TB control was US$ 60 million, 
equivalent to the NTP budget gap reported above. It is estimated that the overall contribution of the 
respective governments to the overall total cost of TB control in 2008 would be 62% (range from 27% in 
Cambodia to 72% in Viet Nam). The share of the total cost provided by the governments of the Philippines 
and China was closely related to average income levels. However, the government contributions relative 
to gross national income level were comparably high in Viet Nam and low in Cambodia. Global Fund will 
be the single most important source of external funding in Cambodia in 2008 and the country will likely 
rely on grant funding to fill the reported funding gap. Figure 18 shows NTP budgets by line item and key TB 
indicators in the four countries with a high burden of TB in the Region. In general, budgets were allocated 
according to the need of each line item; however, the budget for MDR-TB activities seemed too low in 
China and Viet Nam. The budget for first-line anti-TB drugs also seemed too low in China.
FIGuRE 17:  NTP budgets, estimated total TB control cost, and sources of funding in four countries with a high burden of TB in the Region, 
2002–2008
excl. = exclude; NTP = national tuberculosis control programme 
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FIGuRE 18:  NTP budget by line item and key TB indicators in four countries with a high burden of TB in the Region, 2008
For China, the budget for programme management and supervision and for laboratory supplies and equipment was reported as a combined figure, and 
it was assumed the budget allocated 50% for each line item . 
5.2 NTP budgets and estimated costs per patient, 2008
The budget for first-line anti-TB drugs per patient ranged from US$ 19 in Viet Nam to US$ 31 in the 
Philippines. In 2008, it was estimated that the total cost to treat one TB patient will be under US$ 310 
(Figure 19). Overall, the estimated budget for first-line anti-TB drugs per patient in 2008 decreased from 
-30% to -50% from 2002 in three countries (Cambodia, the Philippines, and Viet Nam) and increased 
only in China (+50%). The estimated budget and total cost per patient generally increased at the range 
of +20% to +80% compared to 2002.   
FIGuRE 19:  Estimated total TB control costs and national TB control programme budgets per patient in four countries with a high burden 
of TB, 2008
 
NTP = national tuberculosis control programme
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5.3 Expenditures in 2006 compared with available funding
The total combined expenditure for TB control in 2006 (reported in 2007) from the four countries 
was US$ 175 million: US$ 4 million for Cambodia, US$ 149 million for China, US$ 12 million for the 
Philippines, and US$ 10 million for Viet Nam. In general, countries in the Region successfully mobilized 
and spent financial resources in 2006 into case finding which could be assessed by comparing changes in 
expenditures from 2003–2006 with changes in the number of patients treated in the same period. All four 
countries spent most of the funds available to them (96% for China and the Philippines, 98% in Viet Nam, 
and 91% in Cambodia). 
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6  Profiles of countries with a high 
burden of TB in the Region
This section highlights epidemiologic indicators and detailed estimation of prevalence and mortality 
towards the 2010 goals for seven countries with a high burden of TB in the Region. Overall, these countries 
accounted for 94% of the regional estimated incident cases. 
6.1 Cambodia
The TB control infrastructure in Cambodia is well-established; nonetheless, case detection rates in all forms 
of TB and smear-positive cases have not reached the 70% target. As the NTP services for TB diagnosis 
are decentralizing, TB control in Cambodia now faces the challenge of ensuring quality of services. Major 
obstacles are the limited capacity of staff at all levels, the delay in the detection of TB cases, the difficulty of 
ensuring free-of-charge service, and the irregularity of funds release. Despite high DOTS coverage, services 
are yet to reach to remote, poor and vulnerable populations. 
FIGuRE 20:  Cambodia
TABLE 11:  Key indicators
Population (thousand) 14 197
TB burden (2006 estimate)
Incidence (all forms/100 000 population) 500
Incidence (ss+/100 000 population) 220
Prevalence (all forms/100 000 population) 665
Mortality (deaths/100 000 population) 92
Prevalence of HIV in adult incident TB cases (%) 9 .6
New multidrug-resistant TB cases (%)* 0
Previously treated multidrug-resistant TB cases (%)* 3 .1
*Surveyed in 2001.
30 Tuberculosis Control in the Western Pacific : 2008 Report
6 | PROFILES OF COUNTRIES WITH A HIGH BURDEN OF TB IN THE REGION
TABLE 12:  Surveillance and DOTS implementation (2006)
Notification rate (new and replapse/100 000 population) 244
Notification rate (new ss+/100 000 population) 136
Case detection rate (all new, %) 48
Case detection rate (new ss+, %) 62
DOTS notification rate (new and relapse/100 000 population) 244
DOTS notification rate (new ss+/100 000 population) 136
DOTS case detection (all new, %) 48
DOTS case detection (new ss+, %) 62
DOTS treatment success (2005 cohort new ss+, %) 93
Surveillance and epidemiology
Since 2000, case notification for all forms of TB and new smear-positive cases has increased significantly, 
at rates of +10.0% per year (95% CI, +6.4% to +13.5%) and +4.1% per year (95% CI, +0.7% to +7.5%), 
respectively. Similarly, case detection for all forms of TB and new smear-positive cases has increased 
significantly, at rates of +11.1% per year (95% CI, +7.7% to +14.6%). While overall case detection has 
steadily increased at a rate of +5.2% per year (95% CI, +2.2% to +8.2%) since 2000, the global and Regional 
target to detect 70% of the estimated new smear-positive TB cases was not reached. Case detection rates 
among new smear-positive TB cases dropped from 66% in 2005 to 62% in 2006. Nonetheless, the country 
continued to sustain its high treatment success rate (93% in 2006) among new smear-positive cases and 
100% DOTS coverage. 
FIGuRE 21:  Trend of case notification rates (all forms of TB and smear-positive), 1990–2006
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TABLE 13:  Trend of DOTS performance indicators
2000 2001 2002 2003 2004 2005 2006
DOTS coverage (%) 99 100 100 100 100 100 100
DOTS notification rate (new and relapse)/100 000 population) 148 147 185 209 223 253 244
DOTS notification rate (new ss+/100 000 population) 116 110 130 140 138 149 136
DOTS case detection rate (all new, %) 27 27 35 39 43 49 48
DOTS case detection rate (new ss+, %) 49 47 56 60 60 66 62
DOTS treatment success (new ss+, %) 91 92 92 93 91 93 -
DOTS re-treatment success (ss+, %) 90 92 89 87 86 76 -
Prevalence was estimated to have declined significantly at a rate of -1.6% per year since 2000 (95% CI, 
-2.4% to -0.9%). Given the current estimation, the prevalence would be 635 cases per 100 000 population 
(95% CI, 598 to 674) in 2010, if there is no acceleration in the decline in prevalence.
Mortality was estimated to have declined significantly at a rate of -4.4% per year (95% CI, -6.0% to -2.7%) 
since 2000. Given the current estimation, there would be 74 TB deaths (95% CI, 65 to 84) per 100 000 
population, if there is no acceleration in the decline in mortality.
Estimation of MDR-TB cases
Numbers and proportions of MDR-TB cases that occurred in 2006 in new and re-treatment cases were 
estimated using methods described in Annex 2. In Cambodia, 0 (95% CI, 0 to 332) and 92 (95% CI, 0 to 
221) MDR-TB cases were estimated to have occurred in new and re-treatment TB cases, respectively. 
The prevalence of MDR-TB was 0% (95% CI, 0% to 0.5%) and 3.1% (95% CI, 0.6% to 8.9%) in new and re-
treatment cases, respectively.
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6.2 China
Challenges to TB control in China are related to rapid expansion of DOTS coverage and laboratory capacity. 
The major issue faced by the Chinese NTP is the insufficiency of skilled medical personnel to implement 
DOTS and ensure EQA of sputum microscopy. Alarming rates of MDR-TB in several provinces have given 
China the world’s largest MDR-TB epidemic. But China has the largest budget of MDR-TB globally. Further 
complicating matters, the HIV epidemic is highly heterogeneous. It is low-level in most areas of the country. 
However, there are pockets of higher prevalence, particularly in the western and southern provinces. 
The HIV epidemic in China may move from high-risk groups into the general population; preliminary 
reports suggest that HIV-associated TB is already a serious problem in several counties. In many cities and 
municipalities, the historical decline in TB notification has been reversed in recent years because of the 
increase in TB cases among the internal migrant labour population. 
FIGuRE 23:  China
TABLE 14:  Key indicators
Population (thousand) 1 320 864
TB burden (2006 estimate)
Incidence (all forms/100 000 population) 99
Incidence (ss+/100 000 population) 45
Prevalence (all forms/100 000 population) 201
Mortality (deaths/100 000 population) 15
Prevalence of HIV in adult incident TB cases (%) 0 .3
New multidrug-resistant TB cases (%)* 0 .9-10 .4
Previously treated multidrug-resistant TB cases (%)* 8 .0-41 .9
*Depending on locations (surveyed in 1997 through 2005) .
TABLE 15:  Surveillance and DOTS implementation (2006)
Notification rate (new and replapse/100 000 population) 71
Notification rate (new ss+/100 000 population) 35
Case detection rate (all new, %) 68
Case detection rate (new ss+, %) 79
DOTS notification rate (new and relapse/100 000 population) 71
DOTS notification rate (new ss+/100 000 population) 35
DOTS case detection (all new, %) 68
DOTS case detection (new ss+, %) 79
DOTS treatment success (2005 cohort new ss+, %) 94
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Surveillance and epidemiology
Since 2000, case notification for all forms of TB and new smear-positive cases has increased significantly 
at rates of +13.5% per year (95% CI, +8.5% to +18.5%) and +16.5% per year (95% CI, +9.1% to +24.0%), 
respectively. Case detection for all forms and for new smear-positive cases have also increased significantly 
at rates of +20.2% per year (95% CI, +14.7 to +25.7%) and +19.4% per year (95% CI, +11.4% to +27.4%), 
respectively. The country has sustained 100% DOTS coverage since it reached the target in 2005. Case 
detection and treatment success rates among new smear-positive cases have been remarkably high, 
reporting at 79% and 94%, respectively, in 2006.
FIGuRE 24:  Trend of case notification rates (all forms of TB and smear-positive), 1990–2006
FIGuRE 25:  Case notification rates by age and sex, 2006
TABLE 16:  Trend of DOTS performance indicators
 2000 2001 2002 2003 2004 2005 2006
DOTS coverage (%) 68 68 78 91 96 100 100
DOTS notification rate (new and relapse/100 000 population) 27 28 30 43 58 68 71
DOTS notification rate (new ss+/100 000 population) 15 14 14 20 29 36 35
DOTS case detection rate (all new, %) 24 25 27 37 52 64 68
DOTS case detection rate (new ss+, %) 31 31 30 43 63 80 79
DOTS treatment success (new ss+, %) 95 96 93 94 94 94 -



























































































All forms (trend +13.5%/year; p<0.01)
New ss+ (trend +16.5%/year; p<0.01)
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Prevalence was estimated to have changed at a rate of -3.2% per year since 2000 (95% CI, -7.9% to +1.5%). 
Given the current estimation, the prevalence would be 184 per 100 000 population (95% CI, 127 to 266) in 
2010, if there is no acceleration in the decline in prevalence.
Mortality was estimated to have declined significantly at a rate of -4.7% per year since 2000 (95% CI, -5.8% 
to -3.7%). Given the current estimation, there would be 13 TB deaths per 100 000 population (95% CI, 12 to 
14) in 2010, if there is no acceleration in the decline in mortality.
Estimation of MDR-TB cases
The total number of MDR-TB cases from China accounted for 85% of the total estimated MDR-TB cases in 
the Region. Nearly 66 000 MDR-TB cases (65 853 cases; 95% CI, 41 883 to 90 663) were estimated to have 
occurred in new TB cases in 2006. Among re-treatment cases, there were 64 694 estimated MDR-TB cases 
(95% CI, 41 304 to 88 232). Proportionately, the prevalence of MDR-TB in new and re-treatment cases was 
5% (95% CI, 4.6% to 5.5%) and 25.6% (95% CI, 23.7% to 27.5%), respectively. 
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6.3 The Lao People’s Democratic Republic
The mountainous geography and the low population density in many areas pose challenges to TB control 
activities in the Lao People’s Democratic Republic, increasing the difficulty in communication, monitoring, 
and distribution of supplies and equipment. Staff in remote provinces and districts often receive limited 
support and have fewer resources for TB diagnosis, resulting in a high turn-over of personnel. TB cases 
residing in distant villages have limited access to the district hospital due to distance and costs of 
transportation. Increased involvement of the private sector in TB control activities is expected due to 
economic progress in Vientiane and large provincial capitals.
FIGuRE 26:  The Lao People’s Democratic Republic
TABLE 17:  Key indicators
Population (thousand) 5759
TB burden (2006 estimate)
Incidence (all forms/100 000 population) 152
Incidence (ss+/100 000 population) 68
Prevalence (all forms/100 000 population) 292
Mortality (deaths/100 000 population) 24
Prevalence of HIV in adult incident TB cases (%) 1 .8
New multidrug-resistant TB cases (%) -
Previously treated multidrug-resistant TB cases (%) -
TABLE 18:  Surveillance and DOTS implementation (2006)
Notification rate (new and replapse/100 000 population) 69
Notification rate (new ss+/100 000 population) 53
Case detection rate (all new, %) 44
Case detection rate (new ss+, %) 77
DOTS notification rate (new and relapse/100 000 population) 69
DOTS notification rate (new ss+/100 000 population) 53
DOTS case detection (all new, %) 44
DOTS case detection (new ss+, %) 77
DOTS treatment success (2005 cohort new ss+, %) 90
36 Tuberculosis Control in the Western Pacific : 2008 Report
6 | PROFILES OF COUNTRIES WITH A HIGH BURDEN OF TB IN THE REGION
Surveillance and epidemiology
Since 2000, case notification for all forms of TB and new smear-positive cases has increased significantly, 
at rates of +8.5% per year (95% CI, +6.3% to +10.6%) and +10.9% per year (95% CI, +7.6% to +14.2%), 
respectively. Correspondingly, case detection for all forms of TB and new smear-positive cases has increased 
significantly at rates of +14.8% per year (95% CI, +10.7 to +19.1%) and +11.4% per year (95% CI, +8.0% to 
+14.9%), respectively. The country reached 100% DOTS coverage target in 2005 and has sustained at this 
level in 2006. Case detection and treatment success rates among new smear-positive cases were 77% and 
90%, respectively, in 2006.
FIGuRE 27:  Trend of case notification rates (all forms of TB and smear-positive), 1990–2006
FIGuRE 28:  Case notification rates by age and sex, 2006
TABLE 19:  Trend of DOTS performance indicators
 2000 2001 2002 2003 2004 2005 2006
DOTS coverage (%) 70 75 77 85 98 100 100
DOTS notification rate (new and relapse/100 000 population) 31 30 47 49 55 64 69
DOTS notification rate (new ss+/100 000 population) 29 28 33 33 39 47 53
DOTS case detection rate (all new, %) 19 19 28 31 35 40 44
DOTS case detection rate (new ss+, %) 40 40 46 47 55 68 77
DOTS treatment success (new ss+, %) 77 76 75 79 86 90 -
DOTS re-treatment success (ss+, %) 61 52 66 54 78 87 -
Prevalence was estimated to have declined significantly at a rate of -2 .6% per year since 2000 (95% CI, -3 .2% to -2 .1%) . Given the current estimation, the 



























































































All forms (trend +8.5%/year; p<0.01)
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Mortality was estimated to have declined at a rate of -3.7% per year since 2000 (95% CI, -4.9% to -2.5%). 
Given the current estimation, there would be 20 TB deaths per 100 000 population (95% CI, 18 to 22) in 
2010, if there is no acceleration in the decline in mortality.
Estimation of MDR-TB cases
Some 322 (95% CI, 46 to 1791) estimated MDR-TB cases occurred among new TB cases and 76 (95% CI, 16 to 
241) estimated MDR-TB cases occurred among re-treatment cases in the Lao People’s Democratic Republic 
in 2006. These numbers correspond to 3.7% (95% CI, 0.6% to 19.9%) and 19.4% (95% CI, 4.0 to 58.1%) of the 
new and re-treatment cases, respectively.
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6.4 Mongolia
Major challenges in TB control activities in Mongolia include the distances between health facilities and 
communities, and the poverty characterizing many TB cases. Most TB cases receive the first two months 
of treatment in hospital while the continuation phase is completed on an ambulatory basis. Prisoners, the 
homeless, and unemployed persons are identified as vulnerable groups for TB; treatment success rates 
among these populations are lower compared to the general population. MDR-TB is a continuing challenge 
to TB control in Mongolia, especially among prisoners. 
FIGuRE 29:  Mongolia
TABLE 20:  Key indicators
Population (thousand) 2605
TB burden (2006 estimate)
Incidence (all forms/100 000 population) 188
Incidence (ss+/100 000 population) 85
Prevalence (all forms/100 000 population) 191
Mortality (deaths/100 000 population) 15
Prevalence of HIV in adult incident TB cases (%) 0 .1
New multidrug-resistant TB cases (%)* 1 .4
Previously treated multidrug-resistant TB cases (%) 27 .5
*2008 Survey preliminary data
TABLE 21:  Surveillance and DOTS implementation (2006)
Notification rate (new and replapse/100 000 population) 194
Notification rate (new ss+/100 000 population) 82
Case detection rate (all new, %) 98
Case detection rate (new ss+, %) 97
DOTS notification rate (new and relapse/100 000 population) 194
DOTS notification rate (new ss+/100 000 population) 82
DOTS case detection (all new, %) 98
DOTS case detection (new ss+, %) 97
DOTS treatment success (2005 cohort new ss+, %) 88
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Surveillance and epidemiology
Since 2000, case notification for all forms of TB and for new smear-positive cases has significantly increased 
at a rate of +6.8% per year (95% CI, +5.3% to +8.4%) for both categories. Case detection for all forms of TB 
and for new smear-positive cases has significantly increased at rates of +8.0% per year (95% CI, +5.1% to 
+11.0%) and +6.9% per year (95% CI, +3.2% to +10.7%), respectively. The country has maintained 100% 
DOTS coverage for the past eight consecutive years including 2006. The treatment success rate in new 
smear-positive cases was noted at 88%. 
FIGuRE 30:  Trend of case notification rates (all forms of TB and smear-positive), 1990–2006
FIGuRE 31:  Case notification rates by age and sex, 2006
TABLE 22:  Trend of DOTS performance indicators
 2000 2001 2002 2003 2004 2005 2006
DOTS coverage (%) 100 100 100 100 100 100 100
DOTS notification rate (new and relapse/100 000 population) 123 138 150 151 175 174 194
DOTS notification rate (new ss+/100 000 population) 55 64 65 59 69 71 82
DOTS case detection rate (all new, %) 57 71 71 78 91 87 98
DOTS case detection rate (new ss+, %) 57 73 69 68 80 82 97
DOTS treatment success (new ss+, %) 87 87 87 87 88 88 -
DOTS re-treatment success (ss+, %) 71 72 69 72 70 73 -
Prevalence was estimated to have significantly declined at a rate of -6.3% per year since 2000 (95% CI, 
-7.5% to -5.0%). It was estimated that the prevalence would be 147 per 100 000 population (95% CI, 134 to 
























































































All forms (trend +6.8%/year; p<0.01)
New ss+ (trend +6.8%/year; p=0.01)
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Mortality was estimated to have significantly declined at a rate of -12.3% per year since 2000 (95% CI, 
-18.4% to -6.2%). Given the current estimation, there would be 11 TB deaths per 100 000 population (95% 
CI, 7 to 17) in 2010.
Estimation of MDR-TB cases
It was estimated that there were 48 (95% CI, 9 to 107) MDR-TB cases among new TB cases and 68 (95% CI, 
13 to 204) MDR-TB cases among re-treatment cases. Proportionately, there were 1.0% (95% CI, 0.3% to 
2.5%) of MDR-TB in new TB cases and 20.5% (95% CI, 4.3% to 59.6%) of MDR-TB in re-treatment cases.
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6.5 Papua New Guinea
The Government and churches provide nearly 100% of health care services in Papua New Guinea. Churches 
alone run 46% of health facilities, particularly those that are located in the periphery, using funds provided 
by the national government. Major challenges in TB control in Papua New Guinea include the limited 
availability of resources and staff, affecting implementation of TB control activities. Due to previous 
years’ low performance of TB control in the country, incidence of MDR-TB is likely to be rising, as noted by 
anecdotal reports of the increased number of MDR-TB cases identified by Australian TB services across the 
Torres Strait. Recording and reporting remain incomplete. 
FIGuRE 32:  Papua New Guinea
TABLE 23:  Key indicators
Population (thousand) 6202
TB burden (2006 estimate)
Incidence (all forms/100 000 population) 250
Incidence (ss+/100 000 population) 111
Prevalence (all forms/100 000 population) 513
Mortality (deaths/100 000 population) 48
Prevalence of HIV in adult incident TB cases (%) 4
New multidrug-resistant TB cases (%) -
Previously treated multidrug-resistant TB cases (%) -
TABLE 24:  Surveillance and DOTS implementation (2006)
Notification rate (new and replapse/100 000 population) 203
Notification rate (new ss+/100 000 population) 31
Case detection rate (all new, %) 81
Case detection rate (new ss+, %) 28
DOTS notification rate (new and relapse/100 000 population) 132
DOTS notification rate (new ss+/100 000 population) 24
DOTS case detection (all new, %) 52
DOTS case detection (new ss+, %) 21
DOTS treatment success (2005 cohort new ss+, %) 71
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Surveillance and epidemiology
From 2000 through 2006, case notification in Papua New Guinea has been relatively stable (0% change 
per year; 95% CI, -3.1% to 3.1% for all forms of TB and +1.0% change per year; 95% CI, -9.1% to +11.1% 
for new smear-positive cases). In contrast, case detection for all forms of TB and new smear-positive has 
significantly increased at rates of +17.3% per year (95% CI, +7.3% to +27.3%) and +18.7% per year (95% CI, 
+10.8% to +26.5%), respectively. DOTS coverage dropped from 53% of earlier year to 40% in 2006. While 
the case detection rate in new smear-positive cases has been stable at 21% between 2005 and 2006, the 
treatment success rate has increased from 65% in 2005 to 71% in 2006. 
FIGuRE 33:  Trend of case notification rates (all forms of TB and smear-positive), 1990–2006
FIGuRE 34:  Case notification rates by age and sex, 2006
TABLE 25:  Trend of DOTS performance indicators
 2000 2001 2002 2003 2004 2005 2006
DOTS coverage (%) 8 13 24 46 47 53 40
DOTS notification rate (new and relapse/100 000 population) 53 71 95 98 152 154 132
DOTS notification rate (new ss+/100 000 population) 8 9 17 16 20 23 24
DOTS case detection rate (all new, %) 20 30 37 42 65 61 52
DOTS case detection rate (new ss+, %) 7 9 15 15 19 21 21
DOTS treatment success (new ss+, %) 63 67 53 58 65 71 -

























































































All forms (trend +0%/year; p=1.00)
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Prevalence was estimated to have declined significantly at a rate of -5.2% per year (95% CI, -9.1% to -1.3%) 
from 2000 through 2004. However, there was a significant increase in prevalence starting from 2004 
(+6.8%; 95% CI, +0.01 to +13.5%). Given the current overall exponential decline rate of -5.2% per year, the 
prevalence would be 377 per 100 000 population (95% CI, 277 to 511) in 2010; however, the trend may 
subject to change.
O veral l ,  mor ta l i t y  has  decl ined s igni f icant ly  at  a  rate  of  -4 .6% (95% CI ,  -8 .2% to 
-0.9%) per year from 2000 through 2004. From 2004, however, there was an increase in deaths at a rate of 
+6.7% per year (95% CI, -11.1% to +24.4%). Given the current overall exponential decline rate of -4.4% per 
year, there would be 37 TB deaths per 100 000 population (95% CI, 28 to 49) in 2010; however, the trend 
may subject to change.
Estimation of MDR-TB cases
Overall, more than 900 MDR-TB were estimated to have occurred in Papua New Guinea in 2006, including 
563 (95% CI, 82 to 3 142) cases among new TB cases and 352 (95% CI, 66 to 1092) cases among re-treatment 
cases. Proportionately, there were 3.6% (95% CI, 0.6 to 20.0%) and 19.5% (95% CI, 4.1% to 58.6%) of MDR-TB 
in new and re-treatment cases, respectively. 
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6.6 The Philippines
The Philippines has developed great infrastructure for TB control activities. Collaborative efforts between 
public and private sectors and the establishment of TB diagnostic committees have successfully contributed 
to a dramatic increase in case detection, and decline in the number of over-diagnosis of smear-negative 
cases. Efforts are being made to build on the existing system to mainstream programmatic management 
of MDR-TB activities.  
FIGuRE 35:  The Philippines
TABLE 26:  Key indicators
Population (thousand) 86 264
TB burden (2006 estimate)
Incidence (all forms/100 000 population) 287
Incidence (ss+/100 000 population) 129
Prevalence (all forms/100 000 population) 432
Mortality (deaths/100 000 population) 45
Prevalence of HIV in adult incident TB cases (%) 0 .1
New multidrug-resistant TB cases (%)* 4
Previously treated multidrug-resistant TB cases (%)* 20 .9
*Surveyed in 2004 .
TABLE 27:  Surveillance and DOTS implementation (2006)
Notification rate (new and replapse/100 000 population) 171
Notification rate (new ss+/100 000 population) 99
Case detection rate (all new, %) 58
Case detection rate (new ss+, %) 77
DOTS notification rate (new and relapse/100 000 population) 171
DOTS notification rate (new ss+/100 000 population) 99
DOTS case detection (all new, %) 58
DOTS case detection (new ss+, %) 77
DOTS treatment success (2005 cohort new ss+, %) 89
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Surveillance and epidemiology
Since 2000, case notification for all forms of TB has not changed significantly at a rate of +2.3% per year 
(95% CI, -0.4% to +4.9%), while new smear-positive case notification has significantly increased at a rate of 
+3.5% per year (95% CI, +0.5% to +6.5%). Case detection for all forms of TB and new smear-positive cases 
has significantly increased at rates of +5.9% per year (95% CI, +3.0% to +8.9%) and +7.6% per year 
(95% CI, +5.1% to +10.1%), respectively. DOTS coverage has been sustained at 100% for four consecutive 
years including 2006. In these four years, the country has achieved and maintained high case detection and 
treatment success rates among new smear-positive cases above the 70% and 85% targets, respectively.
FIGuRE 36:  Trend of case notification rates (all forms of TB and smear-positive), 1990–2006
FIGuRE 37:  Case notification rates by age and sex, 2006
TABLE 28:  Trend of DOTS performance indicators
 2000 2001 2002 2003 2004 2005 2006
DOTS coverage (%) 90 95 98 100 100 100 100
DOTS notification rate (new and relapse/100 000 population) 118 139 150 166 160 165 171
DOTS notification rate (new ss+/100 000 population) 66 77 83 91 96 98 99
DOTS case detection rate (all new, %) 39 44 49 55 53 55 58
DOTS case detection rate (new ss+, %) 48 56 61 68 72 75 77
DOTS treatment success (new ss+, %) 88 88 88 88 87 89 -

























































































All forms (trend +2.3%/year; p=0.08)
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Prevalence was estimated to have decreased significantly at a rate of -3.9% per year since 2000 (95% CI, 
-4.9% to -2.8%). Given the current estimation, the prevalence would be 366 per 100 000 population 
(95% CI, 337 to 340) in 2010, if there is no acceleration in the decline in prevalence. 
Mortality was estimated to have decreased significantly at a rate of -4.0% per year since 2000 (95% CI, 
-4.9% to -3.1%). Given the current estimation, there would be 38 TB deaths per 100 000 population 
(95% CI, 36 to 41) in 2010, if there is no acceleration in the decline in mortality.
Estimation of MDR-TB cases
The estimated total MDR-TB cases from the Philippines, ranking the second highest in the Region, 
accounted for 9% of the overall MDR-TB cases: 10 012 (95% CI, 5676 to 15 135) cases among new TB cases 
and 1836 (95% CI, 1007 to 2810) cases among re-treatment cases. Prevalence of MDR-TB was estimated at 
4.0% (95% CI, 2.9% to 5.5%) for new TB cases and 20.9% (95% CI, 14.3% to 29.0%) for re-treatment cases. 
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6.7 Viet Nam
Challenges faced by TB control activities in Viet Nam are related to the rapid spread of HIV since the 
early 1990s. The ongoing spread of the HIV epidemic is expected to exacerbate the number of TB cases. 
However, high political commitment at all levels supports national strategies to respond to the increasing 
number of TB-HIV cases. A TB control network with trained staff has been established nationwide within 
the last decade. However, access barriers to DOTS facilities remain in Viet Nam (e.g., distances, language, 
and stigma). Vulnerable populations include the indigent, ethnic minorities, prisoners, persons detained at 
drug rehabilitation centres, PLWHA, and IDUs. Treatment is not yet available for MDR-TB cases.
FIGuRE 38:  Viet Nam
TABLE 29:  Key indicators
Population (thousand) 86 206
TB burden (2006 estimate)
Incidence (all forms/100 000 population) 173
Incidence (ss+/100 000 population) 77
Prevalence (all forms/100 000 population) 225
Mortality (deaths/100 000 population) 23
Prevalence of HIV in adult incident TB cases (%) 5
New multidrug-resistant TB cases (%)* 2 .7
Previously treated multidrug-resistant TB cases (%)* 19 .3
*Surveyed in 2006 .
TABLE 30:  Surveillance and DOTS implementation (2006)
Notification rate (new and replapse/100 000 population) 113
Notification rate (new ss+/100 000 population) 65
Case detection rate (all new, %) 61
Case detection rate (new ss+, %) 85
DOTS notification rate (new and relapse/100 000 population) 113
DOTS notification rate (new ss+/100 000 population) 65
DOTS case detection (all new, %) 61
DOTS case detection (new ss+, %) 85
DOTS treatment success (2005 cohort new ss+, %) 92
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Surveillance and epidemiology
Since 2000, case notification for all forms of TB and new smear-positive cases has remained unchanged: 
-0.02% per year (95% CI, -1.1% to +0.8%) and -0.6% per year (95% CI, -2.1% to +0.8%), respectively. 
Nonetheless, a prevalence survey conducted recently by the NTP showed a higher prevalence rate than 
previously estimated, indicating that many TB cases may go un-notified. Case detection has also changed 
non-significantly at rates of +0.7% per year (95% CI, -0.1% to +1.6%) for all forms of TB and +0.4% per year 
(95% CI, -1.0% to +1.8%) for new smear-positive cases. However, the country has sustained 100% DOTS 
coverage, high case detection and treatment success rates in new smear-positive cases 2000–2006.
FIGuRE 39:  Trend of case notification rates (all forms of TB and smear-positive), 1990–2006
FIGuRE 40:  Case notification rates by age and sex, 2006
TABLE 31:  Trend of DOTS performance indicators
 2000 2001 2002 2003 2004 2005 2006
DOTS coverage (%) 100 100 100 100 100 100 100
DOTS notification rate (new and relapse/100 000 population) 114 114 118 113 118 113 113
DOTS notification rate (new ss+/100 000 population) 68 68 70 68 70 66 65
DOTS case detection rate (all new, %) 58 59 61 60 62 60 61
DOTS case detection rate (new ss+, %) 82 83 87 85 89 84 85
DOTS treatment success (new ss+, %) 92 93 92 92 93 92 -


























































































All forms (trend -0.2%/year; p=0.70)
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Prevalence was estimated to have significantly declined at a rate of -1.3% per year since 2000 (95% CI, 
-1.2% to -0.5%). Given the current estimation, the prevalence would be 219 per 100 000 population 
(95% CI, 207 to 231) in 2010, if there is no acceleration in the decline in prevalence.
Mortality was estimated to have declined significantly at a rate of -1.1% per year since 2000 (95% CI, -2.4% 
to -0.3%). Given the current estimation, there would be 22 TB deaths per 100 000 population (95% CI, 20 to 
24) in 2010, if there is no acceleration in the decline in mortality.
Estimation of MDR-TB cases
The total number of MDR-TB cases in Viet Nam ranked the third highest in the Region (4% of regional MDR-
TB cases). There were 4047 (95% CI, 2341 to 6056) and 2374 (95% CI, 1378 to 3535) estimated MDR-TB cases 
among new TB and re-treatment cases, respectively. The prevalence of MDR-TB in new TB cases was 2.7% 
(95% CI, 2.0% to 3.6%), while that of re-treatment cases was 19.3% (95% CI, 14.2% to 25.4%).
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7 Summary of the TB burden 
and epidemiologic indicators 
of countries and areas with an 
intermediate burden of TB in the 
Region
7.1  Estimated burden and trend towards 2010 goals
Among the seven countries and areas with an intermediate burden of TB—Brunei Darussalam, 
Hong Kong (China), Japan, Macao (China), Malaysia, the Republic of Korea, and Singapore—the prevalence 
was highest in Malaysia (125 per 100 000 population) and lowest in Singapore (25 per 100 000 
population) (Figure 41). In 2006, there were an estimated 103 727 new TB cases in these countries 
and areas, representing 5.4% of the total TB cases in the Region. Incidence rates were highest in 
Malaysia (103 per 100 000 population) and lowest in Japan (22 per 100 000 population). A total of 
13 334 TB cases were estimated to have died (4.6% of total deaths). Mortality rates were highest in 
Malaysia (17 per 100 000 population) and lowest in Singapore (2 per 100 000 population). Estimated 
prevalence and mortality in 2010 and goals to halve the prevalence and mortality rates of 2000 in countries 
or areas with an intermediate burden of TB in the Region is shown in Table 32. 
FIGuRE 41:  Prevalence, incidence, and mortality rates per 100 000 population in countries and areas with an intermediate burden of TB 
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TABLE 32:  Estimated prevalence and mortality in 2010 and goals to halve the prevalence and mortality rates of 2000 in countries or 
areas with an intermediate burden of TB in the Region
Country and area
Prevalence rate Mortality rate
Annual rate of 
decline a
Estimate in 
2010* Goal in 2010†
Annual rate of 
decline a
Estimate in 
2010* Goal in 2010†
Brunei Darussalam +7 .0% § 28 -10 .1% § 2
Hong Kong (China) -4 .2% 58 44 -4 .8% 4 4
Japan -6 .0% 26 23 -3 .1% 3 2
Macao (China) -4 .2% 61 44 -32 .1% 1 4
Malaysia -1 .6% 120 70 -0 .4% 16 8
Republic of Korea -2 .0% 115 71 -2 .7% 9 6
Singapore -6 .8% 21 20 -9 .2% 2 2
a Average from 2000 through 2006
*Per 100 000 population, assuming current rate of change.
† Per 100 000 population.
§Estimates unreliable due to high proportion of TB among foreign migrant labourers.
7.2 Case notification and trends
Across the intermediate burden countries and areas, 86 462 TB cases (all forms) were notified in 2006, 
including 33 443 smear-positive cases. The largest number of smear-positive cases were reported from 
the Republic of Korea (11 513 cases), followed by Japan (10 159 cases), Malaysia (9414 cases). Case 
notification rates have been declining in these countries and areas since the 1980s (Figure 42). However, in 
Brunei Darussalam and Macao (China), the rates have been fluctuating because of migration and smaller 
populations. The rate of decline is small (1%/year) but stable in Malaysia. 

































 Tuberculosis Control in the Western Pacific : 2008 Report 53
7 | SUMMARY OF THE TB BURDEN AND EPIDEMIOLOGIC INDICATORS OF COUNTRIES AND AREAS WITH AN INTERMEDIATE BURDEN OF TB IN THE REGION
Similar to the pattern seen in the countries with a high burden of TB, TB disproportionately affected males 
and older people (Figure 43). For every female smear-positive TB case older than 14 years, 1.5 to 3.2 male 
smear-positive TB cases were notified. In children younger than 15 years however, equal numbers of each 
sex were notified.
FIGuRE 43:  Smear-positive notification rates, by age and sex, in countries and areas with an intermediate burden of TB, 2006
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7.3 Drug resistance
As of 2006, all countries with an intermediate burden of TB except Brunei Darussalam have conducted DRS. 
The prevalence of resistance to the first line anti-TB drugs are generally low in these countries and areas, 
except in Macao (China) and the Republic of Korea (Table 33). 
The proportion of extensively drug-resistant TB (XDR-TB) among MDR-TB strains tested was 31% in Japan, 
followed by 15% in Hong Kong (China). 
TABLE 33:  Anti-TB drug resistance surveys in countries and areas with an intermediate burden of TB, 2002–2005 .
Country and area Year
New cases Re-treatment cases










Hong Kong (China) 2005 3271 5 .0 0 .9 163 8 .0
Macao (China) 2005 265 10 .6 2 .3 19 15 .8
Japan 2002 2474 2 .8 0 .7 417 9 .8
Republic of Korea 2004 2636 9 .9 2 .7 278 14 .0
Singapore 2004 895 3 .4 0 .2 105 1 .0
# = number; INH = isoniazid; MDR-TB = multidrug-resistance tuberculosis; Malaysia's data was not listed because the DRS was conducted before 2000.
Using data from the Global Project on Anti-tuberculosis Drug Resistance Surveillance, the numbers and 
proportions of MDR-TB cases in new and re-treatment cases estimated to have occurred by country and 
area in 2006 were calculated (see method in Annex 2). Across the seven countries and areas with an 
intermediate burden of TB, there were 1421 (95% CI, 808 to 2201) estimated MDR-TB among new cases, 
corresponding to 1.4% (95% CI, 0.8% to 2.1%) of 103 727 estimated new cases. It was estimated that 1224 
(95% CI, 695 to 2138) MDR-TB cases occurred, corresponding to 11.0% (95% CI, 6.2% to 19.1%) of the 
estimated 11 167 re-treatment cases in the seven countries and areas with an intermediate burden of 
TB in 2006. The 1421 MDR-TB cases from the seven countries and areas with intermediate burden of TB 
represented 1.7% of the total MDR-TB cases estimated to have occurred among new TB cases across the 
Region; likewise, the 1224 MDR-TB cases also represented 1.7% of the total MDR-TB cases estimated to 
have occurred among re-treatment TB cases across the Region.
7.4 TB-HIV
The estimated HIV prevalence among new TB cases in Malaysia (11.0%) and Brunei Darussalam (8.9%) 
ranked the highest and the second-highest across the Region. According to the sentinel surveillance 
data which were collected from four countries and areas with an intermediate burden of TB—
Brunei Darussalam, Hong Kong (China), Macao (China), and Malaysia—the proportion of TB cases tested 
for HIV was high: 82.6% of the total notified TB cases. Of 18 150 TB cases tested, 1477 were identified as 
HIV-infected, representing 8.7% of the total of the tested cases. Of the four countries and areas, only two 
[Hong Kong (China) and Macao (China)] had provided data on CPT and ART among TB-HIV cases. Of the 
33 TB-HIV cases in Hong Kong (China), 19 and 15 were on CPT and ART, respectively. Of the five TB-HIV co-
infected cases in Macao (China), none was on CPT, and two were on ART. 
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7.5 Treatment outcomes
O f the seven countr ies  and areas  with an intermediate  burden of  TB,  there were 
25 068 new smear-positive cases registered for TB treatment in 2005. Treatment success rate was highest 
in Macao (China) (93%) (Figure 44).
FIGuRE 44:  Treatment outcomes for new smear-positive cases registered in 2005 in DOTS areas in countries and areas with an 
intermediate burden of TB in the Region
Numbers in bars show percentages of treatment success outcome .
In Macao (China) and Singapore, death accounted for more than 50% of unfavourable treatment outcomes 
(Figure 45). The largest proportions of unfavourable treatment outcomes in Brunei Darussalam and the 
Republic of Korea were attributable to transfer-out cases. In Brunei Darussalam, many TB cases occur among 
migrant workers who return to their country of origin after they become sputum smear-negative for the 
continuation phase of the treatment. In Japan, the proportion of patients with treatment completed (as 
opposed to cured) is high because sputum examinations may not be conducted at the end of treatment. 
About 26% of cases were not evaluated due to incomplete reporting from physicians to peripheral health 
offices. 
FIGuRE 45:  Unfavourable outcomes among new smear-positive cases registered in 2005 in DOTS areas in countries and areas with an 
intermediate burden of TB in the Region
7.6 Laboratory services
As of 2006, 515 smear microscopy laboratories were established in the seven countries with an intermediate 
burden of TB. The total number of smear microscopy laboratories accredited by EQA was unknown due to 
unavailable data. Of the 515 laboratories, 16 were reported to be capable of performing DST.
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The boundaries shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World 
Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its 
frontiers or boundaries .  
© WHO 2005. All rights reserved
The Pacif ic  is land countr ies  and areas include American Samoa,  Cook Is lands,  Fi j i , 
French Polynesia, Guam, Kiribati, Northern Mariana Islands, Marshall Islands, Micronesia, Nauru, 
New Caledonia, Niue, Palau, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu, and 
Wallis and Futuna (Figure 46). Table 34 shows the key indicators of TB control in the Pacific island countries 
and areas. Prevalence ranged from 12 per 100 000 population in American Samoa to 504 per 100 000 
population in Tuvalu. There were estimated 1249 new TB cases in the Pacific island countries and areas, 
representing 0.06% of the total TB cases in the Region. Incidence rates were highest in Kiribati (372 per 
100 000 population) and lowest in American Samoa (9 per 100 000 population). A total of 163 TB cases 
were estimated to have died (0.06% of the total deaths in the Region). The mortality rate was highest in 
Tuvalu (55 per 100 000 population) and lowest in American Samoa (1 per 100 000 population).
Case notification rates vary across the Pacific island countries and areas (Figure 47). Fluctuation of 
the rates over time is due to the small population sizes of those countries and areas. High notification 
rates were observed in Kiribati:  over 300 cases per 100 000 population in the past several years. 
A consistent and significant decline in case notification rates both for all forms of TB and smear-
58 Tuberculosis Control in the Western Pacific : 2008 Report
8 | SUMMARY OF THE TB BURDEN AND EPIDEMIOLOGIC INDICATORS OF PACIFIC ISLAND COUNTRIES AND AREAS IN THE REGION
positive cases was observed in the Northern Mariana Islands (trend -7.2% per year; 95% CI, -14.2% to 
-0.2% for all forms of TB, trend -12.5%; 95% CI, -18.7% to -6.2% for smear-positive cases) and New Caledonia 
(-11.2% per year; 95% CI, -22.1% to -0.4% for all forms of TB, trend -11.4% per year; 95% CI, -22.2% to -0.5% 
for smear-positive cases). 
Among the four groups of the Pacific island countries and areas (see the grouping in Table 34), the 
incidence rate has steadily declined in Polynesia and Melanesia groups, while it has started climbing up in 
the Micronesia group in 1999. 
TABLE 34:  Key indicators of TB control in the Pacific island countries and areas in the Region, 2006












RateRate Number (%) (% per year)
All ss+ All ss+ All ss+ All ss+ All All
Chamorro group
Guam 171 000 37 17 64 29 69 73 -4 .0 -14 .9* 49 6
Northern Mariana Islands 82 128 75 34 61 28 83 54 -7 .2* -12 .5* 90 10
Micronesia group
Kiribati 93 553 372 168 348 157 107 82 +8 .2 +14 .3 402 45
Marshall Islands 57 962 220 99 127 57 101 79 +21 .1* +24 .6* 241 28
Micronesia 110 617 101 45 112 50 90 82 +0 .1 +22 .2* 109 12
Nauru 10 130 106 48 11 5 112 42 +22 .0* -9 .8 134 15
Palau 20 225 51 23 10 5 116 129 +2 .1 -13 .7 51 4
Polynesia group
American Samoa 65 458 9 4 6 3 69 115 +9 .7 +7 .5 12 1
Cook Islands 13 641 16 7 2 1 47 0 -2 .8 -12 .4 24 3
French Polynesia 259 247 26 12 68 31 98 78 -0 .2 0 29 3
Niue 1 597 43 19 1 0 0 0 - - 85 9
Samoa 185 366 19 9 36 16 64 80 -5 .6 -2 .2 25 3
Tokelau 1 391 56 25 1 0 0 0 - - 112 12
Tonga 99 811 25 11 24 11 74 127 -3 .3 +2 .2 34 3
Tuvalu 10 486 295 133 31 14 29 29 -8 .5 - 504 55
Wallis and Futuna 15 153 46 21 7 3 - - +31 .1 +5 .4 60 7
Melanesia group
Fiji 833 330 22 10 184 83 61 88 -5 .7 -0 .1 30 3
New Caledonia 237 950 27 12 63 28 65 32 -11 .2* -11 .4* 35 4
Solomon Islands 484 022 135 61 655 295 56 42 +3 .0 +2 .8 194 23
Vanuatu 220 772 58 26 128 58 98 73 -10 .1 -8 .8 65 8
Incidence rate, prevalence rate, mortality rate are per 100 000 population.
All = all forms; est. = estimated; Pop. = population; ss+ = smear-positive; - = could not be calculated because of lack of data or data were not reliable; * = statistical significance.
Grouping of the Pacific island countries and areas was used to compare TB epidemiological patterns . Group names were selected based on convenience 
criteria only . This classification does not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal 
status of any country, territory, or area or of its authorities .
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FIGuRE 47:  Case notification rates (all forms of TB and smear-positive cases) in the Pacific island countries and areas in the Region, 
2006 
Panels A, B, C: smoothed lines using moving average method.
A.  Chamorro group
B.  Micronesia group
C.  Polynesia group 25
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D.  Melanesia group
Figure 48 shows TB notification rates are higher in countries and areas with lower per capita gross domestic 
product (GDP). Higher notification rates are observed in countries of Micronesia group and in Tuvalu, where 
overcrowding is common.  
FIGuRE 48:  TB notification rates and gross domestic product in Pacific island countries and areas in the Region, 2000–2006
 
GDP = gross domestic product 
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Annexes
Annex 1:  Estimation of prevalence and TB mortality rates for future years
A linear regression model for each country and area was fitted on log-transformed TB prevalence data that 
were collected annually from the respective countries and areas:
 
with r the prevalence rate per 100 000 population and t expressed in years. The slope 1 can be interpreted 
as a constant rate of change per year assuming an exponential decline of the un-transformed prevalence 
rate. To estimate numbers of prevalent cases in future years for which data were not yet available, predicted 
values of prevalence rates and their respective 95% confidence intervals were estimated. For the estimation 
of mortality rates in future years, a linear regression model was fitted as above by substituting prevalence 
rates with TB mortality rates.
tr 10)ln(  
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Annex 2:  Estimation of MDR-TB prevalence
Based on drug resistance data reported from 114 countries and two special administrative regions of 
China, logistic regression models were fitted to estimate the proportion of MDR-TB among new, previously 
treated, and combined TB cases for a further 69 countries for which surveyed data were not available. 
The estimated number of new TB cases by country and area was used to calculate the number of MDR-
TB cases that occurred among new cases. To estimate the number of previously treated cases for each 
country and area the ratio of notified re-treatment cases to notified new cases in 2006 was multiplied by 
the total number of new cases estimated to have occurred in the same year; therefore, the total number of 
estimated cases included estimated re-treatment cases. 
The method and models were described in detail in: 
Zignol M et al. Global Incidence of Multidrug-resistant Tuberculosis. Journal of Infectious Diseases, 2006, 
194:479-85; and 
The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Anti-Tuberculosis 
Drug Resistance in the World. Fourth Global Report. Geneva, World Health Organization, 2008 (WHO/HTM/
TB//2008.394).
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Annex 3:  Definitions
1.  Definitions of tuberculosis cases
A case of tuberculosis: A patient in whom tuberculosis (TB) has been bacteriologically confirmed or has 
been diagnosed by a clinician. Any person given treatment for TB should be recorded. 
All forms: The sum of new smear-positive pulmonary, relapse, new smear-negative pulmonary and 
extrapulmonary cases.
New smear-positive pulmonary TB: 26 A patient who has never received treatment for TB, or who has 
taken anti-TB drugs for less than 30 days and who has one of the following:
two or more initial sputum smear examinations positive for acid fast bacilli (AFB);•	
one sputum examination positive for AFB plus radiographic abnormalities consistent with active •	
pulmonary TB as determined by a clinician; or
one sputum specimen positive for AFB and at least one sputum that is culture-positive for AFB.•	
New smear-negative pulmonary tuberculosis: A case of pulmonary TB that does not meet the above 
definition for smear-positive TB.
Extrapulmonary tuberculosis: TB of organs other than the lungs, e.g., pleura, lymph nodes, abdomen, 
genito-urinary tract, skin, joints, bones, meninges. Diagnosis should be based on one culture-positive 
specimen, or histological or strong clinical evidence consistent with active extrapulmonary TB, followed by 
a decision by a clinician to treat with a full course of anti-TB chemotherapy. (A patient diagnosed with both 
pulmonary and extrapulmonary TB should be classified as a case of pulmonary TB.)
Re-treatment case: Patient previously treated for TB, undergoing treatment for a new episode of 
bacteriologically positive (sputum smear or culture) TB.
Relapse: A patient previously treated for TB and declared cured or treatment completed, who is later 
diagnosed with bacteriologically positive (culture smear) TB.
2.  Definitions of treatment outcome
Cured
Former smear-positive patient who was smear-negative in the last month of treatment, and on at least 
one previous occasion .
Completed treatment
A patient who has completed treatment but who does not meet the criteria to be classified either as a cure 
or a failure .
Treatment success The sum of patients who are cured and those who have completed treatment .
Died A patient who dies for any reason during the course of treatment .
Failure Smear-positive patient who remained smear-positive at five months or later during treatment .
Defaulted A patient who has interrupted treatment for two consecutive months or more .
Transferred out
A patient who has been transferred to another recording and reporting unit and for whom the treatment 
outcome is not known .
Not evaluated
A patient who did not have the treatment outcome evaluated .
Note: In countries where culture is current practice, patients can be classified as cured or failed based on 
the culture results .
26  The case definition of new smear-positive changed in 2007 and will be applied in future regional reports .
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3.  Indicators to assess treatment outcome
Cure rate: Proportion of cured cases out of all cases registered in a given period (2006, in this report).
Treatment success rate: The sum of the proportion of patients who were cured and patients who 
completed treatment out of all cases registered in a given period. The global target is an 85% cure rate and 
a greater treatment success rate.
The cure rate and treatment success rate are expressed as a percentage of registered cases. The number of 
new cases registered for treatment in 2005 (reported in 2007) is compared to the number of cases notified 
as smear-positive in 2005 (reported in 2006). Differences may arise because NTPs do not compile data at 
the end of each calendar year, diagnoses may be incorrect, patients are lost between diagnosis and the 
start of treatment, or records may be lost. All registered cases should be evaluated. Data on the six standard, 
mutually exclusive outcomes of treatment are compiled. These figures are reported as percentages of all 
registered cases, so that the possible outcomes plus the fraction of cases not evaluated add up to 100%. 
When a country or area states the number of patients registered for treatment, but gives no outcomes, 
no result is reported, rather than reporting zero treatment success. Although treatment outcomes are 
expressed as percentages, they are referred to as rates. The six possible outcomes plus the fraction of cases 
not evaluated add up to 100%. If the number of registered cases is lower than the sum of the six outcomes 
or is missing, the denominator for treatment success will be the number evaluated or the number of smear-
positive cases notified in the previous year, whichever is greater.
4.  Case detection rate and DOTS detection rate
Directly observed treatment, short-course (DOTS)
The recommended strategy for TB control is comprised of:
political commitment with increased and sustained financing; •	
case detection through quality-assured bacteriology;•	
standardized treatment with supervision and patient support;•	
an effective drug supply and management system; and•	
monitoring and evaluation system, and impact measurement.•	
Targets for TB control established by the World Health Assembly (1991)
To cure 85% of the sputum smear-positive TB cases detected.•	
To detect 70% of the estimated new sputum smear-positive TB cases.•	
Case notifications represent only a fraction of the true number of cases in a country or area because the 
coverage by effective NTP may be incomplete.
The estimated cases detection rate is defined as:
Case detection rate (%) = 
 Annual new smear-positive notifications (country and area) 
Estimated annual new smear-positive incidence (country and area)
DOTS detection rate (%) =
 Annual new smear-positive notifications under DOTS 
Estimated annual new smear-positive incidence (country and area
DOTS detection rate
Case detection under DOTS:
Note: The case detection rate and DOTS detection rate are identical when a country or area has a 100% 
DOTS enrolment rate . Updated estimated incidence for 2006 used in this report was provided by World 
Health Organization (WHO) .
Population with access to DOTS: The country and area’s population who live in administrative areas where DOTS services are available .
DOTS enrolment rate (%): This rate indicates a proportion of cases enrolled in DOTS, out of notified cases .
DOTS enrolment rate (all forms) (%) = 
Annual notifications of all forms under DOTS
  Total annual notifications of all forms
DOTS enrolment rate (new ss+) (%) =
 Annual notification of new ss+ under DOTS
   Total annual notifications of new ss+
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5.  Definitions of MDR-TB and XDR-TB
MDR-TB, or multidrug-resistant TB
Strains of TB that are resistant to at least the two main first-line anti-TB drugs—isoniazid and 
rifampicin . 
XDR-TB, or extensively drug-resistant TB
TB that is resistant to any fluoroquinolone, and at least one of three injectable second-line drugs 
(capreomycin, kanamycin, and amikacin), in addition to MDR-TB . The WHO Global Task Force on 
XDR-TB agreed on this definition of XDR-TB in October 2006 .
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Annex 4:  Formulas for estimating tuberculosis incidence, prevalence, and mortality
Formulas Definitions






Is   
N = Population
I = Incidence of tuberculosis (TB) = number of new cases of TB per year




= λk T = TB case notifications (per year)
D = Deaths from TB
4.   D = fl and Ds= fls
IRR = TB incidence rate ratio (TB incidence rate in HIV-positive persons/TB incidence in HIV-
negative persons)
5.   I = Ia
++Ia
-+In
       or







d = Proportion of cases notified (case detection rate)
t = Average duration of TB disease (years)
λ = Rate of infection with Mycobacterium tuberculosis (MTB) (annual rate of infection per person 
per year)
k = Ratio of incidence of smear-positive TB to rate of MTB infection
6 . 
t = Proportion of TB patients who die from TB (case fatality rate [CFR])
m = Prevalence of infection with MTB
7. 
r = Rate of progression to TB disease in MTB-infected individuals (per person per year)
s = Sputum smear-positive TB (no subscript implies all forms)
a = Adult (15–49 years old)
8. n = Other age groups (<15 or >49), assumed HIV-uninfected






* = Attributable to HIV infection
10 . 
h = Prevalence of HIV in new TB cases
p = Prevalence of HIV in the general population
Adapted from: Corbett EL et al . The Growing Burden of Tuberculosis . Global Trends and Interactions with the HIV Epidemic . Archives of Internal 












































 11  IRRp
IRRp
h
 Tuberculosis Control in the Western Pacific : 2008 Report 67
8 | ANNEXES
Annex 5:  Explanatory notes for tables
Regional summary and country and area data are presented in the following 12 tables. All rates are per 
100 000 population.
Table 35: 
Estimated burden of TB, 2000 and 2006
Estimates of incidence, prevalence and mortality for 2000 (baseline year for impact goals endorsed by 
the Regional Committee) and 2006 (the latest year covered by this report). See Annexes 4 for details of 
calculations. All estimates include TB in people living with HIV.
Table 36: 
Whole country and area case notifications and case detection rates, 2006
Case notifications by history (new or re-treatment), by site (pulmonary or extrapulmonary) and by smear 
status (smear-positive, smear-negative, or unknown). Proportions of case types and estimated case 
detection rate for whole country and area (DOTS and non-DOTS combined).
Population, source:•	  World Population Prospects: The 2006 Revision. New York: United Nations 
Population Division, 2007.
Country/Area total:•	  the total number of TB cases according to the country and area’s own reporting 
convention (in many countries this matches the World Health Organization (WHO) total – new 
and relapse; other countries and areas include re-treatment cases and/or cases with unknown 
treatment history).
WHO total:•	  new and relapse cases.
New pulmonary ss+:•	  new pulmonary cases in which diagnosis has been confirmed by smear 
examination.
New pulmonary ss-/unk.:•	  new pulmonary cases in which diagnosis has not been confirmed by 
smear examination or the result is unknown.
New extrapulmonary:•	  new extrapulmonary cases. 
Other new:•	  new cases for which the site of disease is not recorded.
Other re-treat.:•	  re-treatment cases for which the outcome of previous treatment is unknown.
Other:•	  cases for which neither treatment history nor site of disease is recorded.
New pulm. lab. confirm.:•	  new pulmonary cases in which diagnosis has been confirmed by smear 
and/or culture examination.
Case detection rate, all new:•	  notified (all new) cases divided by estimated incident cases (expressed 
as a percentage).
Case detection rate, new ss+:•	  notified new smear-positive cases divided by estimated incident 
smear-positive cases (expressed as a percentage).
ss+ (% of pulm.):•	  the percentage of all new pulmonary cases that are smear-positive.
ss+ (% of new+relapse):•	  the percentage of new and relapse cases that are smear-positive.
Extrapulm. (% of new+relapse):•	   the percentage of all new and relapse cases that are 
extrapulmonary.
Re-treat. (% of new+re-treat.):•	   notified re-treatment cases as a percentage of all notified cases.
Table 37: 
DOTS coverage, case notifications, and case detection rates, 2006
DOTS coverage: the percentage of the national population living in areas where health services have 
adopted DOTS.
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Table 38: 
Laboratory services, management of MDR-TB, and collaborative TB-HIV activities
Laboratory services
Number of laboratories:•	  the number of laboratories working with the national TB control 
programme (NTP) that perform smear microscopy, culture or anti-TB drug susceptibility testing 
(DST), and the number of laboratories performing smear microscopy that are included in external 
quality assessment (EQA).
MDR-TB, 2006
Lab-confirmed MDR among new & re-treat. cases:•	  number of laboratory-confirmed cases of 
multidrug-resistant (MDR)-TB identified among TB patients (new and re-treatment) diagnosed 
in 2006.
DST in new cases:•	  number of new TB cases in 2005 for which DST was performed at start of 
treatment.
MDR in new cases:•	  number of new cases identified as MDR-TB based on DST at start of treatment.
Re-treat. with DST:•	  number re-treatment cases registered in 2006 for which DST was performed at 
start of treatment.
Re-treat. MDR:•	  number of re-treatment cases identified as MDR-TB based on DST at start of 
treatment.
Collaborative TB-HIV activities, 2005 and 2006
TB patients tested for HIV:•	  the number of TB patients tested for HIV.
Of those tested, HIV positive:•	  the number of TB patients found to be HIV-positive.
Of those HIV positive, started co-trimoxazole (CTX):•	  the number of HIV-positive TB patients given 
CPT.
Of those HIV positive, started antiretroviral therapy (ART):•	  the number of HIV-positive TB patients 
given ART during their TB treatment.
Table 39: 
Treatment outcomes, 2005 cohort
Treatment outcomes of new smear-positive cases treated under DOTS, non-DOTS and re-treatment cases 
under DOTS. 
Table 40: 
Re-treatment outcome, 2005 cohort
Re-treatment outcomes of smear-positive cases treated under DOTS after relapse, treatment failure or 
default.
Table 41: 
DOTS treatment success and case detection rates, 1994–2006
Treatment success rates (the proportion of registered cases cured or completed treatment) for new smear-
positive cases treated under DOTS from 1994 to 2005 and smear-positive case detection rates under DOTS 
from 1995 to 2006.
Table 42: 
New smear-positive case notification by age and sex, absolute numbers, DOTS and non-DOTS, 
2006
Breakdown by age and sex of new smear-positive cases notified from whole country and area (DOTS and 
non-DOTS). Some countries and areas cannot provide the breakdown for all smear-positive notified cases.
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Table 43: 
New smear-positive case notification rates by age and sex, DOTS and non-DOTS, 2006
Notification rates of new smear-positive cases by age and sex (DOTS + non-DOTS). Rates are missing where 
breakdown of smear-positive notified cases is not provided, or when age- and sex-specific population 
data are not available. In the regional summary row, rates exclude those countries for which breakdown of 
notified cases or population by age and sex is missing.
Table 44: 
Number of TB cases notified, 1980–2006
Table 45: 
Case notification rates, 1980–2006
Table 46: 
New smear-positive cases notified, numbers and rates, 1993–2006





Incidence, 2000 Prevalence, 2000 TB Mortality, 2000 Incidence, 2006
All forms* Smear-positive* All forms* All forms* All forms* All forms HIV+
number rate number rate number rate number rate number rate number rate
American Samoa 6 10 3 4 8 15 1 2 6 9 – –
Australia 1183 6 531 3 1203 6 118 1 1 329 6 33 0
Brunei Darussalam 187 56 84 25 188 56 14 4 317 83 28 7
Cambodia 67 531 530 30 022 236 102 696 806 12 981 102 70 949 500 6841 48
China 1 342 844 105 604 056 47 3 457 531 271 251 339 20 1 311 184 99 4135 0
Cook Islands 3 18 1 8 5 26 1 3 2 16 – –
Fiji 228 28 102 13 311 38 37 5 184 22 1 0
French Polynesia 92 39 41 17 121 51 14 6 68 26 – –
Guam 65 42 29 19 90 58 7 5 64 37 – –
Hong Kong (China) 5624 85 2529 38 5743 87 484 7 4 433 62 – –
Japan 43 429 34 19 531 15 57 039 45 5257 4 28 330 22 118 0
Kiribati 376 420 169 189 501 559 57 64 348 372 – –
Lao People’s Democratic Republic 8552 162 3848 73 18 272 346 1459 28 8 779 152 161 3
Macao (China) 376 85 169 38 385 87 33 7 283 59 – –
Malaysia 24 821 108 11 144 48 31 979 139 3860 17 26 877 103 2964 11
Marshall Islands 129 248 58 111 224 430 24 47 127 220 – –
Micronesia 137 128 61 57 183 171 21 19 112 101 – –
Mongolia 4987 200 2244 90 7125 285 903 36 4 893 188 7 0
Nauru 15 119 7 54 25 206 3 21 11 106 – –
New Caledonia 85 39 38 18 103 48 12 5 63 27 – –
New Zealand 406 11 183 5 416 11 41 1 352 9 4 0
Niue 1 48 0 22 2 96 0 10 1 43 – –
Northern Mariana Islands 59 84 26 38 59 84 4 6 61 75 – –
Palau 11 58 5 26 22 115 2 8 10 51 – –
Papua New Guinea 13 221 250 5906 111 33 758 637 3131 59 15 473 250 618 10
Philippines 231 295 305 104 074 137 419 962 554 44 195 58 247 740 287 151 0
Republic of Korea 42 177 90 18 965 41 66 370 142 5430 12 42 359 88 314 1
Samoa 41 23 19 11 47 27 5 3 36 19 – –
Singapore 1505 37 674 17 1553 39 170 4 1 128 26 31 1
Solomon Islands 756 181 340 81 1210 289 136 32 655 135 – –
Tokelau 1 56 0 25 2 112 0 12 1 56 – –
Tonga 28 28 12 12 34 34 3 3 24 25 – –
Tuvalu 37 362 17 163 74 723 7 73 31 295 – –
Vanuatu 133 70 60 31 167 87 13 7 128 58 – –
Viet Nam 144 460 184 64 866 82 197 838 251 18 821 24 148 918 173 7416 9
Wallis and Futuna 8 52 3 23 15 103 2 11 7 46 – –
Western Pacific Region 1 934 810 115 869 821 52 4 405 261 261 348 585 21 1 915 285 109 22 823 1
* Incidence, prevalence and mortality estimates include patients with HIV. Estimates labelled “HIV+” are estimates of TB in HIV-positive adults (age 15-49). Estimates for all years are re-calculated as new information becomes 
available and techniques are refined, so they may differ from those published previously. See Explanatory notes on page 67 for further details. Data can be downloaded from http://stoptb.wpro.who.int.
Annex 6:  Tables
TABLE 35:  Estimated burden of TB, 2000 and 2006
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Smear-positive* Smear-positive  HIV+ All forms* All forms HIV+ All forms* All forms HIV+
number rate number rate number rate number rate number rate number rate
3 4 – – 8 12 – – 1 1 – – – American Samoa
595 3 12 0 1341 7 17   133 1 3 0 2 .5 Australia
140 37 10 3 377 99 14   4 43 11 7 2 8 .9 Brunei Darussalam
31 243 220 2394 17  94 433 665 3420   24  13 054 92 2279 16 9 .6 Cambodia
589 619 45 1447 0 2 658 377 201 2068    200 820 15 1170 0 0 .3 China
1 7 – – 3 24 – – 3 – – – Cook Islands
83 10 0 0 254 30    25 3  0 0 .3 Fiji
31 12 – – 75 29 – – 9 3 – – – French Polynesia
29 17 – – 83 49 – – 10 6 – – – Guam
1995 28 – – 4533 64 – – 381 5 – – – Hong Kong (China)
12 736 10 41 0  37 490 29 59   3486 3 13 0 0 .4 Japan
157 168 – – 376 402 – – 42 45 – – – Kiribati
3934 68 57 1  16 846 292 81   1 1368 24 54 1 1 .8 Lao People’s Democratic Republic
127 27 – – 283 59 – – 21 4 – – – Macao (China)
11 798 45 1037 4  32 554 125 1482   6 4515 17 857 3 11 Malaysia
57 99 – – 140 241 – – 16 28 – – – Marshall Islands
50 45 – – 121 109 – – 14 12 – – – Micronesia
2201 85 2 0 4962 191 4   398 15 1 0 0 .1 Mongolia
5 48 – – 14 134 – – 2 15 – – – Nauru
28 12 – – 83 35 – – 9 4 – – – New Caledonia
158 4 2 0 358 9 2   35 1  0 1 .3 New Zealand
0 19 – – 1 85 – – 9 – – – Niue
28 34 – – 74 90 – – 8 10 – – – Northern Mariana Islands
5 23 – – 10 51 – – 1 4 – – – Palau
6901 111 216 3  31 830 513 309   5 3006 48 164 3 4 .0 Papua New Guinea
111 468 129 53 0  372 841 432 75    38 995 45 49 0 0 .1 Philippines
19 030 40 110 0  59 219 123 157   4790 10 34 0 0 .7 Republic of Korea
16 9 – – 47 25 – – 5 3 – – – Samoa
505 12 11 0 1113 25 15   98 2 3 0 2 .7 Singapore
295 61 – – 939 194 – – 111 23 – – – Solomon Islands
0 25 – – 2 112 – – 12 – – – Tokelau
11 11 – – 34 34 – – 3 3 – – – Tonga
14 133 – – 53 504 – – 6 55 – – – Tuvalu
58 26 – – 144 65 – – 17 8 – – – Vanuatu
66 271 77 2596 3  193 946 225 3708   4  19 819 23 1910 2 5 .0 Viet Nam
3 21 – – 9 60 – – 1 7 – – – Wallis and Futuna
859 596 49 7988 0 3 512 972 199  11 412   1  291 240 17 6545 0 1.2 Western Pacific Region
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numbernumber rate number rate
American Samoa 65 4 4 6 3 5  1    
Australia  20 530 1203 1159 6 269 1 405 451 2 32
Brunei Darussalam 382 202 202 53 128 34 15 35 12 12  
Cambodia  14 197  35 466  34 660 244  19 294 136 6875 7800  691 71
China 1 320 864 1 011 388  940 889 71  468 291 35  382 492  38 294 4286  47 526 3003
Cook Islands 14 1 1 7 0 1
Fiji 833 114 114 14 73 9 22 18  1  
French Polynesia 259 69 69 27 24 9 28 15  2  
Guam 171 44 44 26 21 12 15 8
Hong Kong (China) 7132 5773 5356 75 1547 22 2900 699  210  
Japan  127 953  26 384  25 304 20  10 159 8 9098 5203  844  
Kiribati 94 379 378 404 129 138 121 124  4  
Lao People’s Democratic Republic 5759 3994 3958 69 3041 53 457 325 135 18
Macao (China) 478 437 374 78 144 30 174 45  11  
Malaysia  26 114  16 665  16 051 61 9414 36 4336 1920  381 23
Marshall Islands 58 148 138 238 45 78 43 41  9  
Micronesia 111 113 104 94 41 37 37 23 3 3
Mongolia 2605 5216 5049 194 2129 82 724 1922  274 91
Nauru 10 12 12 118 2 20 4 4 2   
New Caledonia 238 50 48 20 9 4 22 10 7
New Zealand 4140 355 344 8 97 2 103 105 30 9  
Niue 2   0  0      
Northern Mariana Islands 82 51 51 62 15 18 32 4
Palau 20 12 12 59 6 30 2 4    
Papua New Guinea 6202  13 532  12 620 203 1948 31 5969 4575  128  
Philippines  86 264  148 217  147 305 171  85 740 99  55 964 1445 4156 74
Republic of Korea  48 050  46 284  37 861 79  11 513 24  18 804 5044  2500 147
Samoa 185 26 25 13 13 7 8 2  2 1
Singapore 4382 1420 1314 30 538 12 525 183 68 4
Solomon Islands 484 371 371 77 124 26 168 74  5  
Tokelau 1   0  0      
Tonga 100 18 18 18 14 14 3 1
Tuvalu 10 9 9 86 4 38 3 2    
Vanuatu 221 132 126 57 42 19 37 47   1
Viet Nam  86 206  98 284  97 363 113  56 437 65  16 645  17 711 6570 558
Wallis and Futuna 15           
Western Pacific Region 1 764 231 1 416 373 1 331 333   75  671 254   38  506 031  86 136 4332  63 580 3994
ss+ = sputum smear-positive; ss- = sputum smear-negative; unk. = sputum smear result unknown; re-treat. = re-treatment; pulm. lab. confirm. = pulmonary case confirmed by positive smear 
or culture. See Explanatory notes on page 67 for further details. Data can be downloaded from http://stoptb.wpro.who.int.
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   3 6 3 69 115 100 75 25  American Samoa
4 36 4 602 1329 595 85 45 40 23 39 6 Australia
   144 317 140 60 91 90 63 17 6 Brunei Darussalam
26 709   19 294  70 949  31 243 48 62 74 56 23 4 Cambodia
3800  23 689  40 007  468 291 1 311 184  589 619 68 79 55 50 4 8 China
2 1 47 0 100 Cook Islands
   73 184 83 61 88 77 64 16 1 Fiji
   51 68 31 98 78 46 35 22 3 French Polynesia
21 64 29 69 73 58 48 18 Guam
13 404  3236 4433 1995 116 78 35 29 13 11 Hong Kong (China)
 1080   10 159  28 330  12 736 86 80 53 40 21 7 Japan
 1  129 348 157 107 82 52 34 33 1 Kiribati
18 3183 8779 3934 44 77 87 77 8 4 Lao People’s Democratic Republic
4 20 39 281 283 127 128 113 45 39 12 9 Macao (China)
164 427   15 311  26 877  11 798 58 80 68 59 12 6 Malaysia
 9 1 45 127 57 101 79 51 33 30 12 Marshall Islands
6 54 112 50 90 82 53 39 22 11 Micronesia
35 41  2129 4893 2201 98 97 75 42 38 8 Mongolia
   2 11 5 112 42 33 17 33  Nauru
2 27 63 28 65 32 29 19 21 15 New Caledonia
 11  156 352 158 95 61 49 28 31 6 New Zealand
    1  0 0     Niue
18 61 28 83 54 32 29 8 Northern Mariana Islands
   6 10 5 116 129 75 50 33  Palau
 912  2076  15 473 6901 81 28 25 15 36 8 Papua New Guinea
52 786  86 308  247 740  111 468 58 77 61 58 1 3 Philippines
356 3699 4221  16 584  42 359  19 030 83 60 38 30 13 16 Republic of Korea
   13 36 16 64 80 62 52 8 12 Samoa
9 83 10 889 1128 505 110 107 51 41 14 12 Singapore
   124 655 295 56 42 42 33 20 1 Solomon Islands
    1  0 0     Tokelau
15 24 11 74 127 82 78 6 Tonga
   4 31 14 29 29 57 44 22  Tuvalu
1  4 42 128 58 98 73 53 33 37 2 Vanuatu
363  56 437  148 918  66 271 61 85 77 58 18 8 Viet Nam
    7 3       Wallis and Futuna
4845  31 913  44 288  685 707 1 915 285  859 596 66 78 57 50 6 8 Western Pacific Region





























numbernumber rate number rate
American Samoa 100 4 6 3 5  1     
Australia 97 1053 5 238 1 361 423 1 30 4
Brunei Darussalam 100 202 53 128 34 15 35 12 12   
Cambodia 100  34 660 244  19 294 136 6875 7800  691 71 26
China 100  940 889 71  468 291 35  382 492  38 294 4286  47 526 3003 3800
Cook Islands 80 1 7 0 1
Fiji 100 114 14 73 9 22 18  1   
French Polynesia 100 69 27 24 9 28 15  2   
Guam 100 44 26 21 12 15 8
Hong Kong (China) 100 3785 53 1116 16 2045 482  142  12
Japan 99  25 060 20  10 068 8 9012 5143  837   
Kiribati 100 378 404 129 138 121 124  4   
Lao People’s Democratic Republic 100 3958 69 3041 53 457 325 135 18 18
Macao (China) 100 374 78 144 30 174 45  11  4
Malaysia 100  16 051 61 9414 36 4336 1920  381 23 164
Marshall Islands 100 138 238 45 78 43 41  9   
Micronesia 98 104 94 41 37 37 23 3 3
Mongolia 100 5049 194 2129 82 724 1922  274 91 35
Nauru 100 12 118 2 20 4 4 2    
New Caledonia 100 48 20 9 4 22 10 7
New Zealand 100 344 8 97 2 103 105 30 9   
Niue 100  0  0       
Northern Mariana Islands 100 51 62 15 18 32 4
Palau 100 12 59 6 30 2 4     
Papua New Guinea 40 8165 132 1481 24 3241 3315  128   
Philippines 100  147 305 171  85 740 99  55 964 1445 4156 74 52
Republic of Korea 100 9982 21 3431 7 5442 145  964  95
Samoa 100 25 13 13 7 8 2  2 1  
Singapore 100 1314 30 538 12 525 183 68 4 9
Solomon Islands 100 371 77 124 26 168 74  5   
Tokelau 0           
Tonga 100 18 18 14 14 3 1
Tuvalu 100 9 86 4 38 3 2     
Vanuatu 100 126 57 42 19 37 47   1 1
Viet Nam 100  97 363 113  56 437 65  16 645  17 711 6570 558 363
Wallis and Futuna            
Western Pacific Region 100 1 297 078 74  662 152 38  488 956  79 672 4331  61 967 3847 4583
ss+ = sputum smear-positive; ss- = sputum smear-negative; unk. = sputum smear result unknown; re-treat. = re-treatment; pulm. lab. Confirmed = pulmonary case confirmed by positive smear or culture. See Explanatory notes 
on page 67 for further details. Data can be downloaded from http://stoptb.wpro.who.int.
TABLE 37:  DOTS coverage, case notifications and case detection rates, 2006
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  3 6 3 69 115 100 75 25  American Samoa
36 4 527 1329 595 77 40 40 23 40 6 Australia
  144 317 140 60 91 90 63 17 6 Brunei Darussalam
709   19 294  70 949  31 243 48 62 74 56 23 4 Cambodia
 23 689  40 007  468 291 1 311 184  589 619 68 79 55 50 4 8 China
2 1 47 0  100  Cook Islands
  73 184 83 61 88 77 64 16 1 Fiji
  51 68 31 98 78 46 35 22 3 French Polynesia
21 64 29 69 73 58 48 18  Guam
303  2207 4433 1995 82 56 35 29 13 11 Hong Kong (China)
1070   10 068  28 330  12 736 86 79 53 40 21 7 Japan
1  129 348 157 107 82 52 34 33 1 Kiribati
3183 8779 3934 44 77 87 77 8 4 Lao People’s Democratic Republic
20  281 283 127 128 113 45 39 12 9 Macao (China)
427   15 311  26 877  11 798 58 80 68 59 12 6 Malaysia
9 1 45 127 57 101 79 51 33 30 12 Marshall Islands
6 54 112 50 90 82 53 39 22 11 Micronesia
41  2129 4893 2201 98 97 75 42 38 8 Mongolia
  2 11 5 112 42 33 17 33  Nauru
2 27 63 28 65 32 29 19 21 15 New Caledonia
11  156 352 158 95 61 49 28 31 6 New Zealand
   1  0 0     Niue
18 61 28 83 54 32 29 8  Northern Mariana Islands
  6 10 5 116 129 75 50 33  Palau
  1609  15 473 6901 52 21 31 18 41 2 Papua New Guinea
786  86 308  247 740  111 468 58 77 61 58 1 3 Philippines
950 969 4892  42 359  19 030 21 18 39 34 1 18 Republic of Korea
  13 36 16 64 80 62 52 8 12 Samoa
83 10 889 1128 505 110 107 51 41 14 12 Singapore
  124 655 295 56 42 42 33 20 1 Solomon Islands
   1        Tokelau
15 24 11 74 127 82 78 6  Tonga
  4 31 14 29 29 57 44 22  Tuvalu
 4 42 128 58 98 73 53 33 37 2 Vanuatu
 56 437  148 918  66 271 61 85 77 58 18 8 Viet Nam
   7 3       Wallis and Futuna
 28 141  40 997  672 353 1 915 285  859 596 64 77 58 51 6 7 Western Pacific Region






Laboratory services Multidrug-resistant TB, 2006




















number smear culture DST
American Samoa          
Australia 127 33 6 127 27 951 17 69 10
Brunei Darussalam 1 1 1   
Cambodia 186 3 1 186      
China 3010 360 90 2770 2 10 2
Cook Islands 1 1   
Fiji 4 1  4  43  1  
French Polynesia 4 2 2   40 2  
Guam 3 2 2 3 1 34 1  
Hong Kong (China) 1 1 1 1 35 3338 27 388 8
Japan          
Kiribati 1      
Lao People’s Democratic Republic 155 135   
Macao (China) 8 1 1 1 7 251 7 27  
Malaysia 241 1 1  42     
Marshall Islands     2 38 3  
Micronesia 5 4 2 21 2 2 2
Mongolia 36 1 1 36 98 48 9 250 89
Nauru 2 2     
New Caledonia 3 3 1 1 1 41 1  
New Zealand 10 10 3 10 1 250 1 16  
Niue       
Northern Mariana Islands 1 1 2 18 2  
Palau 1   1      
Papua New Guinea 60 1 1 15   
Philippines 2374 3 3 2374 403 33 19 424 384
Republic of Korea 260 12 1       
Samoa 1   1   
Singapore 4 2 2 4 6 861 3 101 3
Solomon Islands 9 1 1 9  364  5  
Tokelau       
Tonga 1 1   
Tuvalu 1   1      
Vanuatu 6  3 6   
Viet Nam 874 18 2 740   
Wallis and Futuna          
Western Pacific Region 7390 458 122 6433 629 6331 89 1298 498
ART = antiretroviral treatment; BMU = basic management unit; DST = drug susceptibility testing; EQA = external quality assessment; MDR = multidrug-resistant; re-treat. = re-treatment.
TABLE 38:  Laboratory services, management of MDR-TB and collaborative TB-HIV activities




























        American Samoa
448 22 2 439 22 3 1 Australia
163 2 202 1  Brunei Darussalam
1044 86   3547 342 239 120 Cambodia
 1350 18 26 60 China
   Cook Islands
132 1   114 3 2 2 Fiji
30 26  French Polynesia
46 40  Guam
4209 35 17 19 4511 33 19 15 Hong Kong (China)
        Japan
44 2   Kiribati
 404 51  Lao People’s Democratic Republic
378 1 1 398 5 2 Macao (China)
 11 661 1468    13 039 1438   Malaysia
86 103  Marshall Islands
7 55  Micronesia
1 1 1 1 1 1 1 1 Mongolia
   Nauru
21 25  New Caledonia
140 8   129 10   New Zealand
   Niue
56 50  Northern Mariana Islands
9    9    Palau
   Papua New Guinea
   Philippines
        Republic of Korea
2   Samoa
   Singapore
0        Solomon Islands
0   Tokelau
   Tonga
0        Tuvalu
0   Vanuatu
 14 128 595  14 230 708  Viet Nam
        Wallis and Futuna
 32 605 2221 20 21  38 672 2632 290 201 Western Pacific Region






New smear-positive cases, DOTS  







 Number of cases
Cured
Com -




eval.Notified Regist'd Notified Regist'd
American Samoa 3 4 133 75     25 0 75   
Australia 219 219 100 12 68 9 2 9 0 80 22 22
Brunei Darussalam 101 101 100 66 5 7 0 2 20 0 71  
Cambodia 21 001 21 001 100 89 4 3 0 2 2 0 93   
China 472 719 472 719 100 92 2 2 1 1 1 2 94  
Cook Islands 1 1 100 100 0 0 0 0 0 0 100  
Fiji 63 68 108 71 0 10 0 10 1 7 71   
French Polynesia 21 18 86  89 11 0 0 0 0 89   
Guam 27 27 100 85 0 11 0 0 4 0 85  
Hong Kong (China) 1266 1266 100 74 3 5 11 3 2 1 77 295 295
Japan 9297 10 819 116 38 22 11 3 1  26 60 1634 112
Kiribati 124 123 99 62 31 7 0 1 0 0 93   
Lao People’s Democratic Republic 2806 2802 100 85 5 5 1 3 1 0 90  
Macao (China) 136 136 100 93 0 4 0 1 1 1 93   
Malaysia 8446 8446 100 69 1 9 0 5 6 10 70   
Marshall Islands 48 47 98 85 2 2  2 9 0 87   
Micronesia 32 20 63 75 5 10 5 0 5 0 80  
Mongolia 1868 1868 100 82 6 3 5 3 2 0 88   
Nauru  3  0 67 33 0 0 0 0 67   
New Caledonia 16 16 100 88 6 6 0 0 0 0 94  
New Zealand 83 84 101 0 60 6 0 1 6 27 60   
Niue              
Northern Mariana Islands 15 15 100 73 0 0 0 0 27 0 73  
Palau 3 3 100 100 0 0 0 0 0 0 100   
Papua New Guinea 1346 1292 96 57 14 4 1 19 5 0 71 459  
Philippines 81 647 81 125 99 82 7 2 1 4 2 0 89  
Republic of Korea 3758 3752 100 81 2 1 1 4 11 0 83 7880  
Samoa 11 11 100 91 0 9 0 0 0 0 91   
Singapore 552 548 99 83 14 0 2 1 1 83  
Solomon Islands 169 169 100 56 30 8 0 4 2 0 85   
Tokelau              
Tonga 11 11 100 73 0 18 0 0 9 0 73  
Tuvalu 5 6 120 100 0 0 0 0 0 0 100   
Vanuatu 35 42 120 64 17 10 7 2 0 0 81   
Viet Nam 55 492 55 492 100 90 2 3 1 1 2 0 92  
Wallis and Futuna 1             
Western Pacific Region 661 322 662 254 100 89 3 2 1 1 1 2 92 10 290 429
Not eval. = not evaluated (percentage of registered cases for which outcomes were not recorded); success = sum of cured and completed; cases regist’d, = the denominator for calculating treatment outcomes. The number of 
cases registered for treatment in 2005 is used as the denominator for calculating treatment outcomes unless it is less than the sum of outcomes, in which case the sum of outcomes is used. If the number of cases registered is 
not reported, then the number of cases notified in 2005 is used, or the sum of outcomes if the latter is greater. Data can be downloaded from http://stoptb.wpro.who.int.
TABLE 39:  Treatment outcomes, 2005 cohort
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         1 0 100 0 0 0 0 0 100 American Samoa
100 14 68 18 0 82 39 18 56 3 0 5 18 0 74 Australia
5 40 40 20 0 0 0 0 80 Brunei Darussalam
         1306 49 27 9 2 3 4 7 76 Cambodia
89 239 85 5 3 3 1 1 3 90 China
 0  Cook Islands
                0  Fiji
         4 0 75 25 0 0 0 0 75 French Polynesia
2 50 0 0 0 50 0 0 50 Guam
100 3 1 3 1 0 0 93 3 568 50 23 5 11 8 2 2 73 Hong Kong (China)
7 24 21 4 5 2  44 46 1980 29 16 8 2 2 0 43 45 Japan
         3 100 0 0 0 0 0 0 100 Kiribati
181 75 12 6 2 5 0 1 87 Lao People’s Democratic Republic
         37 51 24 11 0 0 3 11 76 Macao (China)
         1056 46 9 8 1 9 8 19 55 Malaysia
         20 60 10 0 0 0 30 0 70 Marshall Islands
9 11 89 0 0 0 0 0 100 Micronesia
         443 39 34 9 11 4 2 0 73 Mongolia
         1 0 0 0 0 0 0 100 0 Nauru
7 86 0 14 0 0 0 0 86 New Caledonia
         18 0 67 0 0 0 22 11 67 New Zealand
                0  Niue
 0  Northern Mariana Islands
                0  Palau
         65 42 14 15 6 20 3 0 55 Papua New Guinea
  Philippines
         3331 72 3 2 0 6 18 0 75 Republic of Korea
                0  Samoa
149 0 79 15 0 5 0 1 79 Singapore
         5 20 40 20 20 0 0 0 60 Solomon Islands
                  Tokelau
 0  Tonga
                0  Tuvalu
                0  Vanuatu
7374 79 4 5 6 3 3 0 83 Viet Nam
                  Wallis and Futuna
4 9 10 4 2 0 0 75 18 105 843 81 6 3 3 2 2 4 87 Western Pacific Region


























American Samoa               
Australia 16 13 63 25 0 75 2 50
Brunei Darussalam 5 40 40 20 0 0 0 0 80  0 0 0 0
Cambodia 718 75 6 9 1 3 4 2 81 62 34 5 6 23
China 49 707 85 5 3 3 1 1 3 89  
Cook Islands 0 0 0 0 0 0 0 0 0  0 0 0 0
Fiji 0 0 0 0 0 0 0 0 0  0 0 0 0 
French Polynesia 4 75 25 75  
Guam 1 100 0 0 0 0 0 0 100  0 0 0 0
Hong Kong (China) 177 69 7 4 10 4 3 2 76   0 0 0 0 
Japan 862 41 22 10 3 2 23 62  
Kiribati 3 100  0 100      
Lao People’s Democratic Republic 148 78 10 6 1 4 0 1 88      
Macao (China) 14 79 7 0 0 0 14 79 15 47 33 7 7
Malaysia 332 50 11 7 0 6 8 18 60 29 41 3 0  
Marshall Islands 13 85 15     0 100      
Micronesia 1 100 0 100  
Mongolia 216 53 21 11 9 5 2 0 74 94 30 35 10 20
Nauru 1 0 0 0 0 0 0 100 0  0 0 0 0
New Caledonia 1 100 0 0 0 0 0 0 100  0 0 0 0
New Zealand 10 0 60 0 0 0 30 10 60  0 0 0 0
Niue  0 0 0 0 0 0  0  0 0 0 0
Northern Mariana Islands  0 0 0 0 0 0 0  0 0 0 0
Palau  0 0 0 0 0 0  0  0 0 0 0
Papua New Guinea 65 42 14 15 6 20 3 0 55      
Philippines   
Republic of Korea 1074 65 3 2 1 6 24 0 68 5 20 20 0  
Samoa  0 0 0 0 0 0  0  0 0 0 0
Singapore 60 80 18 0 0 0 2 80  
Solomon Islands 5 20 40 20 20 0 0 0 60  0 0 0 0
Tokelau               
Tonga  0 0 0 0 0 0 0  0 0 0 0
Tuvalu  0 0 0 0 0 0  0  0 0 0 0
Vanuatu  0 0 0 0 0 0  0  0 0 0 0
Viet Nam 6325 81 4 5 5 2 3 0 85 577 64 3 5 19
Wallis and Futuna               
Western Pacific Region 59 750 83 5 3 3 1 2 3 88 784 56 8 6 18
Not eval. = not evaluated (percentage of registered cases for which outcomes were not recorded); success = sum of cured and completed; cases regist’d = the denominator for calculating treatment outcomes. The number of cases 
registered for treatment in 2005 is used as the denominator for calculating treatment outcomes unless it is missing or is less than the sum of outcomes, in which case the sum of outcomes is used. Data can be downloaded from 
http://stoptb.wpro.who.int.
TABLE 40:  Re-treatment outcomes, 2005 cohort
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           American Samoa
50 0 50   Australia
0 0 0  0 0 0 0 0 0 0 Brunei Darussalam
3 2 27 39 46 39 24 9 4 13 7 4 63 Cambodia
  China
0 0 0  0 0 0 0 0 0 0 Cook Islands
0 0 0  0 0 0 0 0 0  0 Fiji
         French Polynesia
0 0 0  0 0 0 0 0 0 0 Guam
  24 33 4 4 17 38 0 4 38 Hong Kong (China)
         Japan
           Kiribati
  26 77 12 0 0 0 12 88 Lao People’s Democratic Republic
7 0 0 80 5 20 40 20 0 0 0 20 60 Macao (China)
0 0 55 45 239 44 7 10 1 12 10 15 51 Malaysia
           Marshall Islands
1 100 0 100 Micronesia
1 2 2 65 31 39 23 6 13 10 10 0 61 Mongolia
0 0 0  0 0 0 0 0 0  0 Nauru
0 0 0  0 0 0 0 0 0 0 New Caledonia
0 0 0  0 0 0 0 0 0  0 New Zealand
0 0 0  0 0 0 0 0 0  0 Niue
0 0 0  0 0 0 0 0 0 0 Northern Mariana Islands
0 0 0  0 0 0  0 0  0 Palau
           Papua New Guinea
  Philippines
0  60 40 125 49 2 2 2 20 25 0 51 Republic of Korea
0 0 0  0 0 0 0 0 0  0 Samoa
8 63 13 0 0 25 63 Singapore
0 0 0  0 0 0 0 0 0  0 Solomon Islands
           Tokelau
0 0 0  0 0 0 0 0 0 0 Tonga
0 0 0  0 0 0 0 0 0  0 Tuvalu
0 0 0  0 0 0 0 0 0  0 Vanuatu
5 4 0 68 399 67 5 7 5 11 5 0 72 Viet Nam
           Wallis and Futuna
4 4 4 64 904 55 8 7 4 13 9 5 62 Western Pacific Region




DOTS new smear-positive treatment success (%)
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
American Samoa  100   50 100 100 100 100 100 67 75
Australia    66 75 84 74 66 78 82 85 80
Brunei Darussalam     85 76 63 56 84 60 71 71
Cambodia 84 91 94 91 95 93 91 92 92 93 91 93
China 94 96 96 96 97 96 95 96 93 94 94 94
Cook Islands 100 100 100 100  67  100 100
Fiji 90 86 86 91 90 92 85 85 78 86  71
French Polynesia  67 95 100 74 85 97 80 82 83 80 89
Guam      94 93 71 68 96 100 85
Hong Kong (China)     85 78 76 78 79 78 80 77
Japan      76 70 75 76 76 57 60
Kiribati     83 88 91 86 94 88 94 93
Lao People’s Democratic Republic  70 55 65 80 79 77 76 75 79 86 90
Macao (China) 75   81  78 89 86 89 88 89 93
Malaysia  69    90 78 79 76 72 56 70
Marshall Islands     83 82 91 86 100 90 90 87
Micronesia 64 80    95 93 100 91 92 80 50
Mongolia   78 86 84 86 87 87 87 87 88 88
Nauru      50 25 100 50   67
New Caledonia 62 75   70 77 89 84 85 75 94 94
New Zealand       30 9 60 36 68 60
Niue         100    
Northern Mariana Islands      80 81 74 71 75 88 73
Palau 64 67 75     100 38 80 100 100
Papua New Guinea    93 72 66 63 67 53 58 65 71
Philippines 80  82 83 84 87 88 88 88 88 87 89
Republic of Korea 71 76 71 82     83 82 80 83
Samoa 50 80 100  86 94 92 77 84  100 91
Singapore 88 86    95 85 88 87 77 81 83
Solomon Islands  65 73 92 92  81 89 90 87 87 85
Tokelau             
Tonga 89 75 82 75 94 80 93 92 83 73
Tuvalu           100 100
Vanuatu      88 88 88 79 75 90 81
Viet Nam 91 91 90 85 93 92 92 93 92 92 93 92
Wallis and Futuna        100 100  100  
Western Pacific Region 90 91 93 93 95 94 92 93 90 91 91 92
Treatment success = sum of cured and completed; DOTS new smear-positive case detection rate = notified (new and relapse) cases divided by estimated incident cases. The table includes updated information; data shown here may 
differ from those published in previous reports. Data can be downloaded from http://stoptb.wpro.who.int. 
TABLE 41:  DOTS treatment success and case detection rates, 1994–2006
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DOTS new smear-positive case detection rate (%)
 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
  232  117 78 78 39 78 77 116 115 American Samoa
   22 29 23 19 25 9 32 39 40 Australia
    91 91 91 91 91 91 91 91 Brunei Darussalam
40 34 45 48 54 50 48 57 62 62 68 62 Cambodia
15 29 32 32 30 31 31 30 43 64 80 79 China
126 65 136    165 87 95 99  Cook Islands
57 60 59 68 62 61 74 78 85 70 74 88 Fiji
 74 86 75 76 70  75 59 89 65 78 French Polynesia
     147 161 106 76 94 73 Guam
    64 67 61 65 66 64 61 56 Hong Kong (China)
     23 32 37 46 51 67 79 Japan
  7 33 37 34 40 52 63 90 79 82 Kiribati
 24 33 40 45 40 41 47 48 57 72 77 Lao People’s Democratic Republic
88 136 164 150  95 98 90 99 101 107 113 Macao (China)
64 68    73 73 70 69 67 72 80 Malaysia
   18 29 19 26 31 35 68 84 79 Marshall Islands
12 19    24 13 38 47 65 62 82 Micronesia
7 6 31 61 68 63 74 76 70 82 85 97 Mongolia
     74 38 39 20   42 Nauru
43 55   49 50 50 75 43 60 60 32 New Caledonia
     40 41 51 62 65 50 61 New Zealand
       273     Niue
     103 72 78 59 51 55 54 Northern Mariana Islands
184 81 141     183 103 104 64 129 Palau
  1 7 8 7 8 15 16 17 20 21 Papua New Guinea
0 0 3 10 20 48 56 61 67 72 74 77 Philippines
30 60 56 62     26 23 20 18 Republic of Korea
73 44 71  89 70 60 107 69 65 66 80 Samoa
62 27    16 28 51 57 87 102 107 Singapore
 25 31 40 27 32 36 33 44 49 56 42 Solomon Islands
            Tokelau
67 106 85 126 80 123 67 196 95 70 98 127 Tonga
          35 29 Tuvalu
    40 44 81 53 68 101 60 73 Vanuatu
30 59 78 82 83 82 83 87 85 89 84 85 Viet Nam
      29 30 213  32  Wallis and Futuna
16 28 32 33 32 37 39 39 50 65 77 77 Western Pacific Region
        





0–14 15–24 25–34 35–44 45–54 55–64 65+ 0–14 15–24 25–34 35–44
American Samoa          1  
Australia 1 33 35 23 21 16 43 2 18 27 14
Brunei Darussalam 2 10 11 12 13 10 11 1 5 11 8
Cambodia 50 791 1486 2205 1902 1689 1665 44 749 1330 1839
China 1023 44 528 48 232 56 733 54 301 53 746 68 557 1408 30 904 26 526 24 564
Cook Islands            
Fiji  8 11 4 7 5 4 1 12 5 6
French Polynesia 1 1 1 3 3 1 1 1 6 1  
Guam  1 1 2 3 2 6    1
Hong Kong (China) 3 73 86 136 175 161 443 9 59 98 74
Japan 3 175 436 529 743 1388 3728 5 179 361 280
Kiribati 3 18 18 16 18 3 7 5 15 5 5
Lao People’s Democratic Republic 12 145 245 340 406 345 354 13 109 196 221
Macao (China)  15 6 17 32 19 19 1 7 8 9
Malaysia 15 507 855 734 678 443 496 3 30 300 403
Marshall Islands  4 3 4 6 3 2 2 2 3 3
Micronesia 14 21 3 6 8 6 1 5 23 5 7
Mongolia 7 317 335 241 157 64 41 16 372 265 180
Nauru  1         1
New Caledonia   3 1 1  1  1   
New Zealand 5 14 5 8 4 3 7 1 12 12 12
Niue            
Northern Mariana Islands   2 3 1    2 2 3
Palau 1  1 2 1     1  
Papua New Guinea 32 221 220 122 84 48 3 41 226 215 142
Philippines 419 7878 11 697 13 478 12 733 8074 4640 379 4337 5746 5630
Republic of Korea 19 652 1109 1223 1406 955 1698 27 579 859 507
Samoa  3 2 1 1 1 2  3   
Singapore 2 7 31 67 107 75 106  19 22 22
Solomon Islands 1 13 11 4 4 14 8 4 16 14 9
Tokelau            
Tonga  1   1 2 4  1 1 2
Tuvalu  1       1  1
Vanuatu 1 5 3 1 4 4  2 7 9 2
Viet Nam 49 3761 7549 8931 8717 5037 7408 62 1827 2381 2036
Wallis and Futuna            
Western Pacific Region 1663 59 204 72 397 84 846 81 537 72 114 89 255 2032 39 521 38 404 35 981
TABLE 42:  New smear-positive case notification by age and sex, absolute numbers, DOTS and non-DOTS, 2006




ratio45–54 55–64 65+ 0–14 15–24 25–34 35–44 45–54 55–64 65+
2     1  2    American Samoa
7 9 21 3 51 62 37 28 25 64 1 .8 Australia
11 4 9 3 15 22 20 24 14 20 1 .4 Brunei Darussalam
2072 1915 1557 94 1540 2816 4044 3974 3604 3222 1 .0 Cambodia
18 775 17 782 21 212 2431 75 432 74 758 81 297 73 076 71 528 89 769 2 .3 China
           Cook Islands
4 6  1 20 16 10 11 11 4 1 .1 Fiji
 2 3 2 7 2 3 3 3 4 0 .8 French Polynesia
1 2 2  1 1 3 4 4 8 2 .5 Guam
55 41 134 12 132 184 210 230 202 577 2 .3 Hong Kong (China)
213 256 1863 8 354 797 809 956 1644 5591 2 .2 Japan
1 8 3 8 33 23 21 19 11 10 2 .0 Kiribati
228 222 205 25 254 441 561 634 567 559 1 .5 Lao People’s Democratic Republic
4 3 4 1 22 14 26 36 22 23 3 .0 Macao (China)
321 257 161 18 537 1155 1137 999 700 657 2 .5 Malaysia
7 4 2 2 6 6 7 13 7 4 1 .0 Marshall Islands
4 6 4 19 44 8 13 12 12 5 1 .1 Micronesia
81 24 29 23 689 600 421 238 88 70 1 .2 Mongolia
    1  1    1 .0 Nauru
  2  1 3 1 1  3 2 .0 New Caledonia
3 6 4 6 26 17 20 7 9 11 0 .9 New Zealand
           Niue
1  1  2 4 6 2  1 0 .7 Northern Mariana Islands
   1  2 2 1   5 .0 Palau
75 24 3 73 447 435 264 159 72 6 1 .0 Papua New Guinea
5007 3485 2237 798 12 215 17 443 19 108 17 740 11 559 6877 2 .2 Philippines
403 371 1705 46 1231 1968 1730 1809 1326 3403 1 .6 Republic of Korea
1    6 2 1 2 1 2 2 .5 Samoa
22 27 31 2 26 53 89 129 102 137 2 .8 Singapore
14 8 4 5 29 25 13 18 22 12 0 .8 Solomon Islands
           Tokelau
  2  2 1 2 1 2 6 1 .3 Tonga
1    2  1 1   0 .3 Tuvalu
4   3 12 12 3 8 4  0 .8 Vanuatu
2283 1996 4400 111 5588 9930 10 967 11 000 7033 11 808 2 .8 Viet Nam
           Wallis and Futuna
29 600 26 458 33 598 3695 98 725 110 801 120 827 111 137 98 572 122 853 2.2 Western Pacific Region





0–14 15–24 25–34 35–44 45–54 55–64 65+ 0–14 15–24 25–34 35–44
American Samoa            
Australia 0 2 2 2 1 1 3 0 1 2 1
Brunei Darussalam 3 29 30 42 57 92 177 2 15 28 28
Cambodia 2 46 163 303 397 604 1071 2 45 143 221
China 1 39 45 47 63 96 139 1 30 26 22
Cook Islands            
Fiji 0 9 17 8 16 19 25 1 15 8 12
French Polynesia 3 4 5 14 20 11 15 3 24 5 0
Guam 0 7 8 15 29 31 113 0 0 0 8
Hong Kong (China) 1 16 17 24 29 46 111 2 13 17 10
Japan 0 2 5 6 9 15 34 0 3 4 3
Kiribati            
Lao People’s Democratic Republic 1 23 59 119 201 363 396 1 17 46 73
Macao (China) 0 37 20 46 71 81 120 3 17 22 17
Malaysia 0 20 41 41 49 56 92 0 1 15 23
Marshall Islands            
Micronesia 64 157 42 117 176 249 53 24 189 73 129
Mongolia 2 105 141 132 142 122 93 4 126 113 96
Nauru            
New Caledonia 0 0 16 6 7  14 0 5 0 0
New Zealand 1 5 2 3 1 1 3 0 4 4 4
Niue            
Northern Mariana Islands            
Palau            
Papua New Guinea 2 36 47 34 37 40 4 3 38 46 39
Philippines 3 90 172 270 362 383 310 3 51 86 113
Republic of Korea 0 18 27 29 39 43 87 1 18 22 13
Samoa  16 17 8 13 25 52  19   
Singapore 0 2 11 17 27 32 60 0 7 8 5
Solomon Islands 1 25 27 16 26 145 110 4 34 38 37
Tokelau            
Tonga 0 9 0 0 33 83 136 0 10 16 45
Tuvalu            
Vanuatu 2 21 19 8 50 79 0 5 32 57 16
Viet Nam 0 42 104 152 215 256 332 1 21 33 34
Wallis and Futuna            
Western Pacific Region 1 39 51 56 74 96 129 1 28 28 25
Rates are per 100 000 population of each age/sex group. Rates are calculated excluding those countries for which breakdown of notified cases or population by age and sex is missing. Data can be downloaded from http://stoptb.
wpro.who.int.
TABLE 43:  New smear-positive case notification rates by age and sex, DOTS and non-DOTS, 2006
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Female All
45–54 55–64 65+ 0–14 15–24 25–34 35–44 45–54 55–64 65+
          American Samoa
0 1 1 0 2 2 1 1 1 2 Australia
63 60 151 3 22 29 35 60 80 164 Brunei Darussalam
343 483 527 2 46 153 259 367 533 714 Cambodia
23 34 40 1 34 36 35 44 66 87 China
          Cook Islands
9 21 0 0 12 13 10 13 20 11 Fiji
0 25 42 3 14 5 7 10 18 29 French Polynesia
10 32 33 0 4 4 12 20 31 70 Guam
9 12 29 1 15 17 16 19 29 67 Hong Kong (China)
3 3 12 0 3 4 5 6 9 22 Japan
          Kiribati
109 203 182 1 20 52 95 154 277 277 Lao People’s Democratic Republic
9 16 20 1 27 21 29 40 52 64 Macao (China)
24 34 26 0 11 28 32 37 45 57 Malaysia
          Marshall Islands
88 243 173 45 172 57 123 132 246 119 Micronesia
70 43 49 3 116 127 114 105 81 68 Mongolia
          Nauru
0 0 22 0 2 8 3 4 0 18 New Caledonia
1 3 1 1 4 3 3 1 2 2 New Zealand
          Niue
          Northern Mariana Islands
          Palau
34 20 4 3 37 46 37 35 30 4 Papua New Guinea
139 160 120 3 71 130 191 249 269 205 Philippines
11 16 61 1 18 25 21 25 29 72 Republic of Korea
15    17 9 4 14 13 23 Samoa
6 12 15 0 5 9 11 16 22 36 Singapore
91 85 56 3 29 32 26 58 115 83 Solomon Islands
          Tokelau
0 0 56 0 9 8 22 15 37 92 Tonga
          Tuvalu
51 0 0 3 26 38 12 50 41 0 Vanuatu
55 96 171 0 31 68 92 134 174 246 Viet Nam
          Wallis and Futuna
28 36 42 1 34 40 41 51 67 83 Western Pacific Region
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1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993
American Samoa 2 6 6 8 12 5 8 9 13 5 9 3 1 4
Australia 1457 1386 1270 1219 1299 1088 906 907 954 952 1016 950 1011 991
Brunei Darussalam 196 285 245 276 256 238 212 189 126 128 143  180 160
Cambodia 2576 1980 8158 7572 10 241 10 145 10 325 9106 10 691 7906 6501 10 903 16 148 13 270
China 98 654 117 557 151 564 226 899 265 095 251 600 304 639 310 607 375 481 345 000 320 426 344 218
Cook Islands 8 2 12 15 3 8 3 2  2  1 6 5
Fiji 210 180 163 185 165 230 199 173 162 218 226 247 240 183
French Polynesia 76 66 65 78 80 78 85 80 63 73 59 49 83 78
Guam 55 41 49 48 54 37 49 34 41 75   60 70
Hong Kong (China) 8065 7729 7527 7301 7843 7545 7432 7269 7021 6704 6510 6283 6534 6537
Japan 70 916 65 867 63 940 62 021 61 521 58 567 56 690 56 496 54 357 53 112 51 821 50 612 48 956 48 461
Kiribati 146 187 193 127 111 103 129 110 208 121 68 91 100 99
Lao People’s Democratic Republic 7630  4706 4700 6528 4258 1514 3468 7279 2952 1826 1951 994 2093
Macao (China) 1101 585 233 455 671 571 420 389 320 274 343 329 294 285
Malaysia  11 218  10 970  11 944  11 634  10 577  10 569  10 735  11 068  10 944  10 686  11 702  11 059  11 420  12 285
Marshall Islands 6 7 12 15 12 15 37 32 11 7  26 52 61
Micronesia   67 73 75 66 60 98 77 68 367 350 111 151
Mongolia 1160 1094 1325 1514 1652 2994 2819 2433 2538 2233 1659 1611 1516 1418
Nauru  2 8    8 6 8  7    
New Caledonia 108 128 120 171 144 104 98 74 111 128 143 140 140 104
New Zealand 474 448 437 415 404 359 320 296 295 303 348 335 317 274
Niue 1  2 3 1  5  3    2 1
Northern Mariana Islands  26 75 74 58 64 16 56 27 28 28  67  
Palau 17 10 17 14 20 26 13 38 17 3  6 4 25
Papua New Guinea 2525 2508 2742 2955 3505 3453 2877 2251 4261 3396 2497 3401 2540 7451
Philippines  112 307  116 821  104 715  106 300  151 863  151 028  153 129  163 740  183 113  217 272  317 008  207 371  236 172  178 134
Republic of Korea  89 803  98 532  100 878  91 572  85 669  87 169  88 789  87 419  74 460  70 012  63 904  57 864  48 070  46 999
Samoa 59 49 43 41 37 43 65 29 29 37 44 44 26 49
Singapore 2710 2425 2179 2065 2143 1952 1760 1616 1666 1617 1591 1841 1778 1830
Solomon Islands 266 313 324 302 337 377 292 334 372 488 382 309 364 367
Tokelau  1    2  9 1  1 1 1  
Tonga 64 49 45 50 54 49 35 24 14 36 23 20 29 33
Tuvalu 33 18 12 23 9 32 27 22 24 26 23 30 30 28
Vanuatu 178 92 173 196 188 124 131 90 118 144 140 230 193 114
Viet Nam  43 062  43 506  51 206  43 185  43 875  46 941  47 557  55 505 52 463 52 270 50 203 59 784 56 594 52 994
Wallis and Futuna 23 24 5 17 14 14  34 1 30  22 4 11
Western Pacific Region 356 452 355 337 461 550 462 181 540 985 615 153 651 840 655 006 716 427 741 913 894 073 760 863 754 463 718 783
Number reporting 36 33 36 36 36 36 35 36 36 35 32 31 35 33
% reporting 100 92 100 100 100 100 97 100 100 97 89 86 97 92
From 1995, number shown is all notified new and relapse cases (DOTS and non-DOTS). The table includes updated information; data shown here may differ from those published in previous 
reports. Data can be downloaded from http://stoptb.wpro.who.int.
TABLE 44:  Number of TB cases notified, 1980–2006
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1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
4 6 3 4 3 3 2 3 5 6 4 American Samoa
1057 1073 1145 899 1073 1043 980 1013 949 1059 1046 1159 Australia
160 272 307 216 230 206 176 163 202 Brunei Darussalam
 15 172  14 603  14 857  15 629  16 946  19 266  18 891  19 170  24 610  28 216  30 838  35 535  34 660 Cambodia
 363 804  515 764  504 758  466 394  445 704  449 518  454 372  470 221  462 609  615 868  790 603  894 428  940 889 China
4 2 1 2 3 1 2 1 1 1 1 Cook Islands
225 203 200 171 166 192 144 183 148 185 134 132 114 Fiji
89 86 91 105 93 62 62 64 50 60 63 69 French Polynesia
94 54 63 51 22 50 63 44 Guam
6319 6212 6501 7072 7673 5605 6015 6788 6277 5914 5684 5660 5356 Hong Kong (China)
 44 425  43 078  42 122  42 190  44 016  40 800  39 384  35 489  32 828  31 638  29 736  27 194  25 304 Japan
253 327 464 276 255 252 189 196 284 310 332 378 Kiribati
1135 830 1440 1923 2149 2420 2227 2418 2621 2748 3162 3777 3958 Lao People’s Democratic Republic
402 570 575 465 449 465 388 371 309 355 374 Macao (China)
 11 708  11 778  12 691  13 539  14 115  14 908  15 057  14 830  14 389  15 671  14 986  15 342  16 051 Malaysia
59 49 41 34 56 51 60 117 111 138 Marshall Islands
173 172 126 107 123 91 104 127 99 118 98 104 Micronesia
1730 2780 4062 3592 2915 3348 3109 3526 3829 3918 4542 4601 5049 Mongolia
4 2 4 3 5 3 11 12 Nauru
97 87 104 88 90 78 94 61 65 38 61 47 48 New Caledonia
352 391 352 321 365 447 344 377 329 386 371 332 344 New Zealand
2 2 1 4 Niue
46 48 51 93 97 66 75 58 53 45 53 57 51 Northern Mariana Islands
41 19 5 15 32 11 9 5 10 12 Palau
5335 8041 3195 7977  11 291  13 003  10 520  12 658  11 197  12 798  12 743  12 564  12 620 Papua New Guinea
 180 044  119 186  165 453  195 767  162 360  145 807  119 914  107 133  118 408  132 759  130 530  137 100  147 305 Philippines
 38 155  42 117  39 315  33 215  34 661  32 075  21 782  37 268  34 967  33 843  34 389  38 290  37 861 Republic of Korea
45 45 31 32 22 31 43 22 31 27 34 24 25 Samoa
1677 1889 1951 1977 2120 1805 1728 1536 1516 1581 1414 1356 1314 Singapore
332 352 299 318 295 289 302 292 256 293 340 397 371 Solomon Islands
2 Tokelau
23 20 22 21 30 22 24 12 29 16 12 18 18 Tonga
19 36 18 14 16 16 13 30 12 9 Tuvalu
152 79 126 184 178 120 152 175 101 104 115 76 126 Vanuatu
 51 763  55 739  74 711  77 838  87 468  88 879  89 792  90 728  95 044  92 741  98 173  94 916  97 363 Viet Nam
11 6 8 14 1 19 15 7 Wallis and Futuna
 724 290  824 954  873 425  870 920  834 599  820 469  786 285  805 105  811 482  980 890 1 160 130 1 274 124 1 331 333 Western Pacific Region
33 29 31 31 30 32 34 35 35 36 32 36 35 Number reporting
92 81 86 86 83 89 94 97 97 100 89 100 97 % reporting
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1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993
American Samoa 6 18 17 22 32 13 19 21 29 11 19 6 2 8
Australia 10 9 8 8 8 7 6 6 6 6 6 6 6 6
Brunei Darussalam 102 143 120 131 118 107 92 80 52 51 56  66 57
Cambodia 38 29 114 102 132 125 123 104 118 84 67 109 155 124
China   10 11 14 21 24 23 27 27 33 30 27 29
Cook Islands 45 11 68 85 17 45 17 11 0 11 0 6 33 28
Fiji 33 28 24 27 24 32 28 24 23 30 31 34 32 24
French Polynesia 50 42 41 47 47 45 48 44 34 38 30 25 41 38
Guam 52 38 44 42 46 31 40 27 32 57   43 50
Hong Kong (China) 160 150 144 137 145 138 135 131 126 119 114 109 111 109
Japan 61 56 54 52 51 48 47 46 44 43 42 41 39 39
Kiribati 267 333 335 214 182 164 200 166 304 172 95 124 135 132
Lao People’s Democratic Republic 246  145 141 191 121 42 93 190 75 45 46 23 47
Macao (China) 437 226 87 163 229 186 131 117 92 76 92 86 75 72
Malaysia 82 78 83 78 69 67 67 67 64 61 65 59 60 63
Marshall Islands 20 22 36 43 33 39 92 76 25 15  54 105 122
Micronesia   86 91 90 77 68 109 84 72 381 354 110 146
Mongolia 70 64 76 84 89 157 143 120 121 103 75 71 66 61
Nauru 0 26 104 0 0 0 96 70 91 0 77    
New Caledonia 76 88 81 114 94 67 62 46 68 76 84 80 78 57
New Zealand 15 14 14 13 13 11 10 9 9 9 10 10 9 8
Niue 29 0 64 100 35 0 190 0 125  0  89 44
Northern Mariana Islands  139 355 308 214 213 49 157 70 68 64  135  
Palau 139 80 134 108 150 191 94 269 118 21  39 25 155
Papua New Guinea 79 77 82 86 99 95 77 59 109 84 60 80 58 167
Philippines 234 237 207 205 286 278 275 287 314 363 518 331 368 272
Republic of Korea 236 255 257 230 212 214 215 210 177 165 149 134 110 106
Samoa 38 32 28 26 24 27 41 18 18 23 27 27 16 30
Singapore 112 98 86 80 81 72 64 57 58 55 53 59 56 56
Solomon Islands 116 132 132 119 128 139 104 116 125 160 122 96 110 107
Tokelau 0 64 0 0 0 126 0 559 62 0 62 63 64  
Tonga 66 51 47 53 58 53 38 26 15 38 24 21 30 34
Tuvalu 410 221 145 274 106 370 307 245 263 280 244 315 312 289
Vanuatu 152 77 141 156 146 94 97 65 83 99 94 150 122 70
Viet Nam 81 80 93 76 76 79 79 90 83 81 76 88 82 75
Wallis and Futuna 200 200 40 130 104 101  243 7 216  158 29 78
Western Pacific Region 27 27 34 34 39 44 46 45 49 50 59 50 49 46
Rates are per 100 000 population. The table includes updated information; data shown here may differ from those published in previous reports. Data can be downloaded from http://stoptb.wpro.who.int.
TABLE 45:  Case notification rates, 1980–2006
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1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
8  0 11 5 7 5 5 3 5 8 9 6 American Samoa
6 6  6 5 6 5 5 5 5 5 5 6 Australia
   52  84 92 63 66 58 48 44 53 Brunei Darussalam
137 128 127 130 138 154 148 147 186 209 225 255 244 Cambodia
30 42 41 38 36 36 36 37 36 47 61 68 71 China
22 11 6 11 0 18 6 13 7 0 7 7 7 Cook Islands
30 26 26 22 21 24 18 23 18 23 16 16 14 Fiji
42  39 41 46 40 26 26 26 20 24 25 27 French Polynesia
66      35 40 32 13 30 37 26 Guam
104 100 103 111 118 85 90 101 92 86 81 80 75 Hong Kong (China)
36 34 33 33 35 32 31 28 26 25 23 21 20 Japan
332  417 582 340 309 300 221 225 320 343 361 404 Kiribati
25 18 30 39 43 47 43 45 49 50 57 67 69 Lao People’s Democratic Republic
 98 136 136 108  102 104 85 80 66 75 78 Macao (China)
58 57 60 62 64 66 65 62 59 63 59 60 61 Malaysia
  115  95 79 65 106 95 110 211 196 238 Marshall Islands
163 160 117 99 114  85 97 118 91 108 89 94 Micronesia
73 116 169 148 119 136 126 142 153 155 178 178 194 Mongolia
41     20 40 30 50 30  109 118 Nauru
51 45 53 44 44 37 44 28 29 17 26 20 20 New Caledonia
10 11 9 9 10 12 9 10 8 10 9 8 8 New Zealand
88 0 91 0 0 51 0 0 228 0 0 0 0 Niue
83 83 85 149 150 99 109 81 72 59 68 71 62 Northern Mariana Islands
247 111 29 83  169   56 45 25 50 59 Palau
116 171 66 161 221 248 195 229 198 221 215 207 203 Papua New Guinea
268 174 236 273 222 195 157 138 149 164 158 162 171 Philippines
86 94 87 73 75 69 47 79 74 71 72 80 79 Republic of Korea
27 27 18 19 13 18 24 12 17 15 19 13 13 Samoa
50 54 54 53 56 46 43 37 36 37 33 31 30 Singapore
94 97 80 83 75 71 73 68 58 65 74 84 77 Solomon Islands
0 135 0   0 0 0  0  0 0 Tokelau
24 21 23 21 31 22 24 12 29 16 12 18 18 Tonga
195 367   179 138 157 156 126 290  115 86 Tuvalu
90 46 72 103 98 65 80 90 51 51 55 35 57 Vanuatu
72 76 100 103 114 114 114 113 117 112 117 112 113 Viet Nam
77 42 55 96    7 127 100  46  Wallis and Futuna
46 51 54 53 50 49 47 47 47 57 67 73 75 Western Pacific Region





1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
American Samoa 1 4   6 2 3 2 2 1 2 2
Australia 557    226 203 285 251 228 210 113 285
Brunei Darussalam 68      102 84 95 112 121 115
Cambodia   11 058  11 101  12 065  12 686  13 865  15 744  14 822  14 361  17 258  18 923  18 978
China  84 898  104 729  134 488  203 670  236 021  202 817  201 775  204 765  204 591  194 972  267 414  384 886
Cook Islands 5 4 2 1 2    2 1  1
Fiji 61 62 68 69 66 74 65 62 73 74 78 62
French Polynesia  38  37 41 34 33 29  28 21 30
Guam  40      43 47 31  22
Hong Kong (China) 2429   1774 1943 2091 1536 1940 1857 1892 1794 1693
Japan  17 890  16 770  14 367  12 867  13 571  11 935  12 909  11 853  11 408  10 807  10 843  10 471
Kiribati 99 184  144 50 52 59 54 64 82 99 142
Lao People’s Democratic Republic   478 886 1234 1494 1706 1526 1563 1829 1866 2226
Macao (China) 108  141 258 325 276  160 157 147 138 128
Malaysia 6954 6861 6688 7271 7496 7802 8207 8156 8309 7958 7989 7843
Marshall Islands 12   12  11 17 11 15 18 20 39
Micronesia   9 14 9 14  15 8 22 26 35
Mongolia  145 455 769 1171 1356 1513 1389 1631 1670 1541 1808
Nauru  2     2 4 2 2 1  
New Caledonia 16 28 21 26 24 26 22 20 19 21 12 15
New Zealand 91 61 78 90 83 106 94 74 68 88 106 111
Niue    1   1   1   
Northern Mariana Islands   14 26 21 26 15 27 19 21 16 14
Palau 8 11 9 4 7  20   9 5 5
Papua New Guinea   1652 447 1195 2107 2140 1933 1351 1345 2310 1896
Philippines  92 279  87 401  94 768  86 695  80 163  69 476  73 373  67 056  59 341  65 148  72 670  78 163
Republic of Korea  16 630  13 266  11 754  11 420 9957  10 359 9559 8216  11 805  11 345  10 976  11 471
Samoa 21 18 15 9 14 7 17 13 11 19 12 11
Singapore 513 861 455 519 436 482 465 248 357 549 583 501
Solomon Islands 155 114 109 90 113 140 93 109 118 108 138 152
Tokelau   1          
Tonga 16 17 9 14 11 16 10 15 8 23 11 8
Tuvalu 2 1 6          
Vanuatu  62 30 50 66 38 43 63 57 38 40 59
Viet Nam    37 550  48 911  50 016  54 889  53 805  53 169  54 238  56 698  55 937  58 394
Wallis and Futuna   3 3 1    1 1 7  
Western Pacific Republic  222 813  241 737  314 271  388 142  416 954  379 698  383 613  376 109  371 806  372 528  453 812  579 566
Rates are per 100 000 population. The table includes updated information; data shown here may differ from those published in previous reports. Data can be downloaded from http://stoptb.wpro.who.int/.
TABLE 46:  New smear-positive cases notified, numbers and rates, 1993–2006
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Rate (per 100 000 population)
2005 2006 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
3 3 2 8  0 11 4 5 4 3 2 3 3 5 5 American Samoa
241 269 3    1 1 2 1 1 1 1 1 1 1 Australia
101 128 24    0  31 25 28 32 34 31 27 34 Brunei Darussalam
 21 001  19 294  100 97 103 106 113 126 116 110 130 140 138 150 136 Cambodia
 472 719  468 291 7 9 11 17 19 16 16 16 16 15 21 29 36 35 China
1  28 22 11 6 11 0 0 0 13 7 0 7 7 0 Cook Islands
63 73 8 8 9 9 8 9 8 8 9 9 10 8 8 9 Fiji
21 24  18  17 18 15 14 12 0 11 8 12 8 9 French Polynesia
27 21  28      28 30 19 0 13 16 12 Guam
1561 1547 41  0 28 30 32 23 29 28 28 26 24 22 22 Hong Kong (China)
 10 931  10 159 14 13 11 10 11 9 10 9 9 8 8 8 9 8 Japan
124 129 132 241  184 63 64 71 64 75 94 112 157 135 138 Kiribati
2806 3041   10 18 25 30 33 29 29 34 34 40 50 53 Lao People’s Democratic Republic
136 144 27  34 62 77 64  36 35 32 30 27 29 30 Macao (China)
8446 9414 36 34 32 34 35 35 36 35 35 33 32 31 33 36 Malaysia
48 45 24   23  21 33 21 28 34 37 70 85 78 Marshall Islands
32 41   8 13 8 13  14 7 20 24 32 29 37 Micronesia
1868 2129 0 6 19 32 48 56 62 56 66 67 61 71 72 82 Mongolia
 2  20     20 40 20 20 10  0 20 Nauru
16 9 9 15 11 13 12 13 10 9 9 9 5 7 7 4 New Caledonia
83 97 3 2 2 2 2 3 2 2 2 2 3 3 2 2 New Zealand
  0 0 0 45 0 0 51 0 0 57 0 0 0 0 Niue
15 15   24 43 34 40 22 39 27 29 21 18 19 18 Northern Mariana Islands
3 6 50 66 53 23 39  106   46 25 25 15 30 Palau
1805 1948   35 9 24 41 41 36 24 24 40 32 30 31 Papua New Guinea
 81 647  85 740 141 130 138 124 112 95 98 88 76 82 90 94 97 99 Philippines
 11 638  11 513 38 30 26 25 22 22 21 18 25 24 23 24 24 24 Republic of Korea
11 13 13 11 9 5 8 4 10 7 6 11 7 6 6 7 Samoa
552 538 16 26 13 14 12 13 12 6 9 13 14 12 13 12 Singapore
169 124 45 32 30 24 30 36 23 26 28 25 31 33 36 26 Solomon Islands
   0 68 0   0 0 0  0  0 0 Tokelau
11 14 17 18 9 14 11 16 10 15 8 23 11 8 11 14 Tonga
5 4 21 10 61    0 0 0 0 0  48 38 Tuvalu
35 42  37 17 28 37 21 23 33 29 19 20 28 16 19 Vanuatu
 55 492  56 437   51 66 66 71 69 67 68 70 68 70 65 65 Viet Nam
1    21 21 7    7 7 47  7  Wallis and Futuna
 671 612  671 254 14 15 20 24 25 23 23 22 22 22 26 33 38 38 Western Pacific Republic
94 Tuberculosis Control in the Western Pacific : 2008 Report
Country
New TB cases Re-treatment cases
Number Percentage Number Percentage
Est. Min. Max. Est. Min. Max. Est. Min. Max. Est. Min. Max.
Cambodia 0 0 332 0 .0 0 .0 0 .5 92 0 221 3 .1 0 .6 8 .9
China 65 853 41 883 90 663 5 .0 4 .6 5 .5 64 694 41 304 88 232 25 .6 23 .7 27 .5
Lao People’s Democratic Republic 322 46 1791 3 .7 0 .6 19 .9 76 16 241 19 .4 4 .0 58 .1
Mongolia 48 9 107 1 .0 0 .3 2 .5 68 13 204 20 .5 4 .3 59 .6
Papua New Guinea 563 82 3142 3 .6 0 .6 20 .0 352 66 1082 19 .5 4 .1 58 .6
Philippines 10 012 5676 15 135 4 .0 2 .9 5 .5 1836 1007 2810 20 .9 14 .3 29 .0
Viet Nam 4047 2341 6056 2 .7 2 .0 3 .6 2374 1378 3535 19 .3 14 .2 25 .4
Western Pacific Region 82 087 57 531 107 804 4.4 3.9 4.8 70 601 47 134 94 543 24.4 22.7 26.1
Est. = estimated; Min. = lower 95% CI bound; Max. = upper 95% CI bound
Annex 7:  Multidrug-resistant TB 
TABLE 47:  Estimated numbers and proportion of MDR-TB cases in new TB and re-treatment cases in countries with a high burden of TB, 2006
Annex 8:  Notified prevalence of resistance to anti-TB drugs (1997–2006)
TABLE 48:  Notified prevalence of resistance to specific drugs among new TB cases tested for resistance
Country and 







tance % Any H % Any R % Any E % Any S % Mono % Mono H % Mono R %
Australia Countrywide 2005 Surveillance
combined 
only
 .  .  .  .  .  .  .  .  .
Cambodia Countrywide 2001 Survey 638 572 89 .7 66 10 .3 41 6 .4 4 0 .6 1 0 .2 32 5 .0 54 8 .5 30 4 .7 3 0 .5
China Beijing 2004 Survey 1043 856 82 .1 187 17 .9 91 8 .7 44 4 .2 43 4 .1 95 9 .1 113 10 .8 35 3 .4 11 1 .1
China Henan 2001 Survey 1222 858 70 .2 364 29 .8 208 17 .0 117 9 .6 53 4 .3 271 22 .2 190 15 .5 40 3 .3 17 1 .4
China Heilongjiang 2005 Survey 1574 1005 63 .9 569 36 .1 268 17 .0 167 10 .6 93 5 .9 383 24 .3 340 21 .6 61 3 .9 34 2 .2




2002 Survey 806 524 65 .0 282 35 .0 164 20 .3 79 9 .8 72 8 .9 172 21 .3 148 18 .4 40 5 .0 13 1 .6
Fiji Countrywide 2006 Surveillance
combined 
only
 .  .  .  .  .  .  .  .  .
Guam Countrywide 2002 Survey
combined 
only
 .  .  .  .  .  .  .  .  .
Hong  Kong 
 (China)
Hong Kong 2005 Surveillance 3271 2909 88 .9 362 11 .1 164 5 .0 36 1 .1 27 0 .8 274 8 .4 262 8 .0 66 2 .0 7 0 .2
Japan Countrywide 2002 Surveillance 2705 2472 91 .4 233 8 .6 77 2 .8 28 1 .0 23 0 .9 188 7 .0 184 6 .8 33 1 .2 5 0 .2
Macao 
 (China)






 .  .  .  .  .  .  .  .  .
New  
Zealand
Countrywide 2006 Surveillance 250 224 89 .6 26 10 .4 17 6 .8 1 0 .4 1 0 .4 18 7 .2 17 6 .8 8 3 .2 0 0 .0
Northern   
Mariana  
Islands
Countrywide 2006 Surveillance 18 4 22 .2 4 22 .2 3 16 .7 2 11 .1 0 0 .0 2 11 .1 1 5 .6 0 0 .0 0 0 .0
Philippines Countrywide 2004 Survey 965 767 79 .5 198 20 .5 130 13 .5 44 4 .6 41 4 .2 115 11 .9 122 12 .6 57 5 .9 4 0 .4
Republic  
of  Korea
Countrywide 2004 Survey 2636 2315 87 .8 321 12 .2 261 9 .9 98 3 .7 70 2 .7 70 2 .7 203 7 .7 145 5 .5 25 0 .9






 .  .  .  .  .  .  .  .  .
Vanuatu Countrywide 2006 Surveillance 29 28 96 .6 1 3 .4 1 3 .4 0 0 .0 0 0 .0 0 0 .0 1 3 .4 1 3 .4 0 0 .0
Viet Nam Countrywide 2006 Survey 1619 1122 69 .3 497 30 .7 310 19 .1 53 3 .3 42 2 .6 375 23 .2 291 18 .0 114 7 .0 5 0 .3
H = isoniazid; R = rifampicin; E = ethanbutol; S = streptomicin; Mono = mono-resistant to; HR = resistant only to H and R; HRE = resistant to H, R and E; 
HRS = resistant to H, R and S; HRES = resistant to H, R, E, and S; Poly = resistant to more than one drug other than MDR; HE = resistant to H and E;  
HS = resistant to H and S; HES = resistant to H, E, and S; RE = resistant to R and E; RS = resistant to R and S; RES = resistant to R, E, and S;  
ES = resistant to E and S.





S % MDR % HR % HRE % HRS % HRES % Poly % HE % HS % HES % RE % RS % RES % ES %
 .  .  .  .  .  .  .  .  .  .  .  .  .  .  . Australia
0 0 .0 21 3 .3 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 12 1 .9 1 0 .2 10 1 .6 0 0 .0 0 0 .0 1 0 .2 0 0 .0 0 0 .0 Cambodia
14 1 .3 53 5 .1 24 2 .3 15 1 .4 1 0 .1 5 0 .5 3 0 .3 50 4 .8 11 1 .1 21 2 .0 0 0 .0 5 0 .5 4 0 .4 0 0 .0 9 0 .9 Beijing 
10 0 .8 123 10 .1 95 7 .8 18 1 .5 5 0 .4 47 3 .8 25 2 .0 79 6 .5 2 0 .2 62 5 .1 9 0 .7 1 0 .1 4 0 .3 0 0 .0 1 0 .1 Henan 
3 0 .2 242 15 .4 113 7 .2 24 1 .5 63 4 .0 4 0 .3 22 1 .4 116 7 .4 0 0 .0 93 5 .9 1 0 .1 1 0 .1 18 1 .1 1 0 .1 2 0 .1 Heilongjiang 
0 0 .0 26 3 .4 30 3 .9 7 0 .9 17 2 .2 1 0 .1 5 0 .7 31 4 .1 1 0 .1 29 3 .8 0 0 .0 0 0 .0 1 0 .1 0 0 .0 0 0 .0 Shanghai
5 0 .6 90 11 .2 59 7 .3 13 1 .6 29 3 .6 4 0 .5 13 1 .6 75 9 .3 9 1 .1 44 5 .5 12 1 .5 1 0 .1 6 0 .7 0 0 .0 3 0 .4
Inner 
Mongolia
 .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Fiji
 .  .  .  .  .  .  .  .  .  .  .  .  .  .  . Guam
1 0 .0 188 5 .7 28 0 .9 5 0 .2 3 0 .1 9 0 .3 11 0 .3 72 2 .2 5 0 .2 60 1 .8 5 0 .2 1 0 .0 0 0 .0 0 0 .0 1 0 .0
Hong Kong 
(China)
2 0 .1 144 5 .3 19 0 .7 2 0 .1 3 0 .1 3 0 .1 11 0 .4 30 1 .1 0 0 .0 21 0 .8 4 0 .1 0 0 .0 2 0 .1 2 0 .1 1 0 .0 Japan
0 0 .0 13 4 .9 6 2 .3 0 0 .0 0 0 .0 3 1 .1 3 1 .1 8 3 .0 0 0 .0 7 2 .6 1 0 .4 0 0 .0 0 0 .0 0 0 .0 0 0 .0
Macao 
(China)
 .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
New 
Caledonia
0 0 .0 9 3 .6 1 0 .4 0 0 .0 0 0 .0 0 0 .0 1 0 .4 8 3 .2 0 0 .0 8 3 .2 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0
New 
Zealand




1 0 .1 60 6 .2 39 4 .0 10 1 .0 5 0 .5 5 0 .5 19 2 .0 37 3 .8 5 0 .5 21 2 .2 8 0 .8 1 0 .1 0 0 .0 0 0 .0 2 0 .2 Philippines
7 0 .3 26 1 .0 71 2 .7 24 0 .9 33 1 .3 4 0 .2 10 0 .4 47 1 .8 16 0 .6 26 1 .0 3 0 .1 1 0 .0 1 0 .0 0 0 .0 0 0 .0
Republic 
of Korea
2 0 .2 23 2 .6 2 0 .2 0 0 .0 0 0 .0 0 0 .0 2 0 .2 12 1 .3 2 0 .2 9 1 .0 1 0 .1 0 0 .0 0 0 .0 0 0 .0 0 0 .0 Singapore
 .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Solomon 
Islands
0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 Vanuatu
3 0 .2 169 10 .4 44 2 .7 0 0 .0 0 0 .0 20 1 .2 24 1 .5 162 10 .0 0 0 .0 143 8 .8 9 0 .6 0 0 .0 4 0 .2 0 0 .0 6 0 .4 Viet Nam
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Country and 





tance % Any H % Any R % Any E % Any S % Mono % Mono H % Mono R %
Australia Countrywide 2005 Surveillance combined only  .  .  .  .  .  .  .  .  .
Cambodia Countrywide 2001 Survey 96 79 82 .3 17 17 .7 16 16 .7 3 3 .1 0 0 .0 7 7 .3 10 10 .4 9 9 .4 0 0 .0
China Beijing 2004 Survey 154 100 64 .9 54 35 .1 38 24 .7 23 14 .9 14 9 .1 33 21 .4 17 11 .0 7 4 .5 2 1 .3
China Henan 2001 Survey 265 104 39 .2 161 60 .8 125 47 .2 113 42 .6 48 18 .1 114 43 .0 38 14 .3 11 4 .2 8 3 .0
China Heilongjiang 2005 Survey 421 137 32 .5 284 67 .5 202 48 .0 170 40 .4 103 24 .5 136 32 .3 101 24 .0 37 8 .8 24 5 .7




2002 Survey 308 92 29 .9 216 70 .1 174 56 .5 157 51 .0 98 31 .8 92 29 .9 52 16 .9 23 7 .5 16 5 .2
Fiji Countrywide 2006 Surveillance combined only  .  .  .  .  .  .  .  .  .
Guam Countrywide 2002 Survey combined only  .  .  .  .  .  .  .  .  .
Hong Kong 
(China)
Hong Kong 2005 Surveillance 163 125 76 .7 38 23 .3 28 17 .2 16 9 .8 9 5 .5 25 15 .3 15 9 .2 7 4 .3 1 0 .6
Japan Countrywide 2002 Surveillance 417 312 74 .8 105 25 .2 79 18 .9 46 11 .0 35 8 .4 60 14 .4 49 11 .8 26 6 .2 2 0 .5
Macao 
(China)
Macao 2005 Surveillance 19 14 73 .7 5 26 .3 4 21 .1 3 15 .8 1 5 .3 3 15 .8 2 10 .5 1 5 .3 0 0 .0
New 
Caledonia
Countrywide 2005 Survey combined only  .  .  .  .  .  .  .  .  .
New 
Zealand




Countrywide 2006 Surveillance new only  .  .  .  .  .  .  .  .  .
Philippines Countrywide 2004 Survey 129 81 62 .8 48 37 .2 40 31 .0 33 25 .6 12 9 .3 22 17 .1 17 13 .2 10 7 .8 5 3 .9
Republic 
of Korea
Countrywide 2004 Survey 278 201 72 .3 77 27 .7 67 24 .1 47 16 .9 27 9 .7 16 5 .8 29 10 .4 20 7 .2 7 2 .5
Singapore Countrywide 2005 Surveillance 105 94 89 .5 11 10 .5 4 3 .8 3 2 .9 1 1 .0 7 6 .7 9 8 .6 2 1 .9 2 1 .9
Solomon 
Islands
Countrywide 2004 Survey combined only  .  .  .  .  .  .  .  .  .
Vanuatu Countrywide 2006 Surveillance new only  .  .  .  .  .  .  .  .  .
Viet Nam Countrywide 2006 Survey 207 85 41 .1 122 58 .9 90 43 .5 44 21 .3 30 14 .5 105 50 .7 38 18 .4 8 3 .9 2 1 .0
H = isoniazid; R = rifampicin; E = ethanbutol; S = streptomicin; Mono = mono-resistant to; HR = resistant only to H and R; HRE = resistant to H, R and E; 
HRS = resistant to H, R and S; HRES = resistant to H, R, E, and S; Poly = resistant to more than one drug other than MDR; HE = resistant to H and E;  
HS = resistant to H and S; HES = resistant to H, E, and S; RE = resistant to R and E; RS = resistant to R and S; RES = resistant to R, E, and S;  
ES = resistant to E and S.
TABLE 49:  Notified prevalence of resistance to specific drugs among previously treated TB cases tested for resistance





S % MDR % HR % HRE % HRS % HRES % Poly % HE % HS % HES % RE % RS % RES % ES %
 .  .  .  .  .  .  .  .  .  .  .  .  .  .  . Australia
0 0 .0 1 1 .0 3 3 .1 1 1 .0 0 0 .0 2 2 .1 0 0 .0 4 4 .2 0 0 .0 4 4 .2 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 Cambodia
0 0 .0 8 5 .2 18 11 .7 6 3 .9 2 1 .3 7 4 .5 3 1 .9 19 12 .3 3 1 .9 8 5 .2 2 1 .3 1 0 .6 2 1 .3 0 0 .0 3 1 .9 Beijing 
4 1 .5 15 5 .7 97 36 .6 20 7 .5 2 0 .8 41 15 .5 34 12 .8 26 9 .8 0 0 .0 13 4 .9 4 1 .5 2 0 .8 5 1 .9 1 0 .4 1 0 .4 Henan 
0 0 .0 40 9 .5 128 30 .4 25 5 .9 58 13 .8 6 1 .4 39 9 .3 55 13 .1 3 0 .7 32 7 .6 2 0 .5 1 0 .2 17 4 .0 0 0 .0 0 0 .0 Heilongjiang 
1 0 .5 5 2 .5 25 12 .5 6 3 .0 10 5 .0 2 1 .0 7 3 .5 11 5 .5 0 0 .0 7 3 .5 0 0 .0 0 0 .0 2 1 .0 1 0 .5 1 0 .5 Shanghai
0 0 .0 13 4 .2 129 41 .9 34 11 .0 48 15 .6 6 1 .9 41 13 .3 35 11 .4 2 0 .6 17 5 .5 3 1 .0 1 0 .3 9 2 .9 2 0 .6 1 0 .3
Inner
Mongolia
 .  .  .  .  .  .  .  .  .  .  .  .  .  .  . Fiji
 .  .  .  .  .  .  .  .  .  .  .  .  .  .  . Guam
1 0 .6 6 3 .7 13 8 .0 3 1 .8 0 0 .0 4 2 .5 6 3 .7 10 6 .1 0 0 .0 8 4 .9 0 0 .0 1 0 .6 0 0 .0 1 0 .6 0 0 .0
Hong Kong 
(China)
1 0 .2 20 4 .8 41 9 .8 6 1 .4 6 1 .4 10 2 .4 19 4 .6 15 3 .6 3 0 .7 6 1 .4 3 0 .7 1 0 .2 0 0 .0 2 0 .5 0 0 .0 Japan
0 0 .0 1 5 .3 3 15 .8 1 5 .3 0 0 .0 1 5 .3 1 5 .3 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0
Macao 
(China)
 .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
New 
Caledonia
0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0
New 
Zealand




0 0 .0 2 1 .6 27 20 .9 7 5 .4 4 3 .1 8 6 .2 8 6 .2 4 3 .1 0 0 .0 3 2 .3 0 0 .0 0 0 .0 1 0 .8 0 0 .0 0 0 .0 Philippines
0 0 .0 2 0 .7 39 14 .0 14 5 .0 16 5 .8 4 1 .4 5 1 .8 9 3 .2 4 1 .4 3 1 .1 1 0 .4 0 0 .0 0 0 .0 1 0 .4 0 0 .0
Republic 
of Korea
0 0 .0 5 4 .8 1 1 .0 0 0 .0 0 0 .0 0 0 .0 1 1 .0 1 1 .0 0 0 .0 1 1 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 Singapore
 .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Solomon 
Islands
 .  .  .  .  .  .  .  .  .  .  .  .  .  .  . Vanuatu
2 1 .0 26 12 .6 40 19 .3 5 2 .4 0 0 .0 15 7 .2 20 9 .7 44 21 .3 0 0 .0 34 16 .4 8 3 .9 0 0 .0 2 1 .0 0 0 .0 0 0 .0 Viet Nam
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Country and 












Australia Countrywide 2005 Surveillance 808 726 89 .9 82 10 .1 71 8 .8 14 1 .7 7 0 .9 35 4 .3 53 6 .6 43 5 .3 1 0 .1
Cambodia Countrywide 2001 Survey 734 651 88 .7 83 11 .3 57 7 .8 7 1 .0 1 0 .1 39 5 .3 64 8 .7 39 5 .3 3 0 .4
China Beijing 2004 Survey 1197 956 79 .9 241 20 .1 129 10 .8 67 5 .6 57 4 .8 128 10 .7 130 10 .9 42 3 .5 13 1 .1
China Henan 2001 Survey 1487 962 64 .7 525 35 .3 333 22 .4 230 15 .5 101 6 .8 385 25 .9 228 15 .3 51 3 .4 25 1 .7
China Heilongjiang 2005 Survey 1995 1142 57 .2 853 42 .8 470 23 .6 337 16 .9 196 9 .8 519 26 .0 441 22 .1 98 4 .9 58 2 .9
China Shanghai 2005 Survey 964 791 82 .1 173 17 .9 128 13 .3 67 7 .0 43 4 .5 87 9 .0 76 7 .9 36 3 .7 8 0 .8
China Inner Mongolia 2002 Survey 1114 616 55 .3 498 44 .7 338 30 .3 236 21 .2 170 15 .3 264 23 .7 200 18 .0 63 5 .7 29 2 .6
Fiji Countrywide 2006 Surveillance 38 38 100 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0
Guam Countrywide 2002 Survey 47 45 95 .7 2 4 .3 4 8 .5 2 4 .3 1 2 .1 2 4 .3 0 0 .0 0 0 .0 0 0 .0
Hong Kong 
(China)
Hong Kong 2005 Surveillance 4350 3873 89 .0 477 11 .0 228 5 .2 57 1 .3 36 0 .8 353 8 .1 336 7 .7 92 2 .1 12 0 .3
Japan Countrywide 2002 Surveillance 3122 2784 89 .2 338 10 .8 156 5 .0 74 2 .4 58 1 .9 248 7 .9 233 7 .5 59 1 .9 7 0 .2
Macao 
(China)
Macao 2005 Surveillance 284 237 83 .5 47 16 .5 32 11 .3 10 3 .5 5 1 .8 30 10 .6 30 10 .6 15 5 .3 1 0 .4
New 
Caledonia
Countrywide 2005 Survey 5 4 80 .0 1 20 .0 1 20 .0 0 0 .0 0 0 .0 1 20 .0 0 0 .0 0 0 .0 0 0 .0
New 
Zealand







 .  .  .  .  .  .  .  .  .
Philippines Countrywide 2004 Survey 1094 848 77 .5 246 22 .5 170 15 .5 77 7 .0 53 4 .8 137 12 .5 139 12 .7 67 6 .1 9 0 .8
Republic 
of Korea
Countrywide 2004 Survey 2914 2516 86 .3 398 13 .7 328 11 .3 145 5 .0 97 3 .3 86 3 .0 232 8 .0 165 5 .7 32 1 .1
Singapore Countrywide 2005 Surveillance 1000 931 93 .1 69 6 .9 34 3 .4 8 0 .8 8 0 .8 42 4 .2 53 5 .3 18 1 .8 5 0 .5
Solomon 
Islands
Countrywide 2004 Survey 84 84 100 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0
Vanuatu Countrywide 2006 Surveillance
new 
only
 .  .  .  .  .  .  .  .  .
Viet Nam Countrywide 2006 Survey 1826 1207 66 .1 619 33 .9 400 21 .9 97 5 .3 72 3 .9 480 26 .3 329 18 .0 122 6 .7 7 0 .4
H = isoniazid; R = rifampicin; E = ethanbutol; S = streptomicin; Mono = mono-resistant to; HR = resistant only to H and R; HRE = resistant to H, R and E; 
HRS = resistant to H, R and S; HRES = resistant to H, R, E, and S; Poly = resistant to more than one drug other than MDR; HE = resistant to H and E;  
HS = resistant to H and S; HES = resistant to H, E, and S; RE = resistant to R and E; RS = resistant to R and S; RES = resistant to R, E, and S;  
ES = resistant to E and S.
TABLE 50:  Notified prevalence of resistance to specific drugs among all TB cases tested for resistance 





S % MDR % HR % HRE % HRS % HRES % Poly % HE % HS % HES % RE % RS % RES % ES %
0 0 .0 9 1 .1 12 1 .5 1 0 .1 1 0 .1 5 0 .6 5 0 .6 17 2 .1 1 0 .1 15 1 .9 0 0 .0 0 0 .0 1 0 .1 0 0 .0 0 0 .0 Australia
0 0 .0 22 3 .0 3 0 .4 1 0 .1 0 0 .0 2 0 .3 0 0 .0 16 2 .2 1 0 .1 14 1 .9 0 0 .0 0 0 .0 1 0 .1 0 0 .0 0 0 .0 Cambodia
14 1 .2 61 5 .1 42 3 .5 21 1 .8 3 0 .3 12 1 .0 6 0 .5 69 5 .8 14 1 .2 29 2 .4 2 0 .2 6 0 .5 6 0 .5 0 0 .0 12 1 .0 Beijing 
14 0 .9 138 9 .3 192 12 .9 38 2 .6 7 0 .5 88 5 .9 59 4 .0 105 7 .1 2 0 .1 75 5 .0 13 0 .9 3 0 .2 9 0 .6 1 0 .1 2 0 .1 Henan 
3 0 .2 282 14 .1 241 12 .1 49 2 .5 121 6 .1 10 0 .5 61 3 .1 171 8 .6 3 0 .2 125 6 .3 3 0 .2 2 0 .1 35 1 .8 1 0 .1 2 0 .1 Heilongjiang 
1 0 .1 31 3 .2 55 5 .7 13 1 .3 27 2 .8 3 0 .3 12 1 .2 42 4 .4 1 0 .1 36 3 .7 0 0 .0 0 0 .0 3 0 .3 1 0 .1 1 0 .1 Shanghai
5 0 .4 103 9 .2 188 16 .9 47 4 .2 77 6 .9 10 0 .9 54 4 .8 110 9 .9 11 1 .0 61 5 .5 15 1 .3 2 0 .2 15 1 .3 2 0 .2 4 0 .4
Inner 
Mongolia
0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 Fiji
0 0 .0 0 0 .0 2 4 .3 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 Guam
2 0 .0 230 5 .3 41 0 .9 8 0 .2 3 0 .1 13 0 .3 17 0 .4 100 2 .3 5 0 .1 85 2 .0 5 0 .1 2 0 .0 1 0 .0 1 0 .0 1 0 .0
Hong Kong 
(China)
3 0 .1 164 5 .3 60 1 .9 8 0 .3 9 0 .3 13 0 .4 30 1 .0 45 1 .4 3 0 .1 27 0 .9 7 0 .2 1 0 .0 2 0 .1 4 0 .1 1 0 .0 Japan
0 0 .0 14 4 .9 9 3 .2 1 0 .4 0 0 .0 4 1 .4 4 1 .4 8 2 .8 0 0 .0 7 2 .5 1 0 .4 0 0 .0 0 0 .0 0 0 .0 0 0 .0
Macao 
(China)
0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 1 20 .0 0 0 .0 1 20 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0
New 
Caledonia
0 0 .0 9 3 .4 1 0 .4 0 0 .0 0 0 .0 0 0 .0 1 0 .4 8 3 .0 0 0 .0 8 3 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0
New 
Zealand




1 0 .1 62 5 .7 66 6 .0 17 1 .6 9 0 .8 13 1 .2 27 2 .5 41 3 .7 5 0 .5 24 2 .2 8 0 .7 1 0 .1 1 0 .1 0 0 .0 2 0 .2 Philippines
7 0 .2 28 1 .0 110 3 .8 38 1 .3 49 1 .7 8 0 .3 15 0 .5 56 1 .9 20 0 .7 29 1 .0 4 0 .1 1 0 .0 1 0 .0 1 0 .0 0 0 .0
Republic 
of Korea
2 0 .2 28 2 .8 3 0 .3 0 0 .0 0 0 .0 0 0 .0 3 0 .3 13 1 .3 2 0 .2 10 1 .0 1 0 .1 0 0 .0 0 0 .0 0 0 .0 0 0 .0 Singapore
0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0
Solomon 
Islands
 .  .  .  .  .  .  .  .  .  .  .  .  .  .  . Vanuatu
5 0 .3 195 10 .7 84 4 .6 5 0 .3 0 0 .0 35 1 .9 44 2 .4 206 11 .3 0 0 .0 177 9 .7 17 0 .9 0 0 .0 6 0 .3 0 0 .0 6 0 .3 Viet Nam
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TABLE 51:  Notified prevalence of extensively drug resistant TB (XDR-TB) among MDR-TB, 2002–2007
Country and Area Source Year Method MDR
MDR 
tested 









Representative survey or 
surveillance data
Australia Global Project, SRLs Australia
2002-
2005
surveillance 43 43 4 9 .3 1 2 .3
Hong Kong (China) Global Project, SRL Hong Kong 2005 surveillance 41 41 12 29 .3 6 14 .6
Japan Global Project, SRL Japan 2002 sentinel 60 55 21 38 .2 17 30 .9
Macao (China) Global Project 2005 surveillance 9 9 1 11 .1 0 0
New Zealand Global Project 2005 surveillance 4 4 2 50 0 0




surveillance 14 14 1 7 .1 0 0
Risk groups and MDR-TB 
treatment programmes
Philippines






 293 149 50 .9 45 56 .7 10 3 .4 1 .6 6 .2
FLQ = resistant to fluroquinolone; CI = confidence interval; SRL = Supranational Reference Laboratory; Tx = treatment; GLC: Green Light Committee
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This report can also be downloaded at: 
http://stoptb.wpro.who.int/



